

# International Guidelines on Good Governance Practice for Research Institutions

CIOMS Working Group report Draft

12 April 2023

This report was posted for comment on 12 April 2023 at:

[https://cioms.ch/working\\_groups/principles-of-good-governance-for-research-institutions/](https://cioms.ch/working_groups/principles-of-good-governance-for-research-institutions/)

The CIOMS Working Group (WG) GGPRI (Good Governance Practice for Research Institutions) welcomes your input to the report, or any parts of it. A list of GGPRI WG members can be found at the end of the document.

Please note that the layout will be improved in the final version, and best efforts will be made to correct remaining typographical and/or grammatical errors, as well those pertaining to references.

Permissions are being sought to reproduce some of the illustrative materials included in this report. We welcome responses from organizations that own any of these materials and have not yet been contacted in this regard.

Please submit your comments using the form posted on the CIOMS website : [https://cioms.ch/working\\_groups/principles-of-good-governance-for-research-institutions/](https://cioms.ch/working_groups/principles-of-good-governance-for-research-institutions/). The timeline for submission of comments is 7 June 2023. Thank you.

Copyright © 2022 by the Council for International Organizations of Medical Sciences (CIOMS)

All rights reserved. CIOMS publications may be obtained directly from CIOMS through its publications e-module at <https://cioms.ch/publications/>. Further information can be obtained from CIOMS, P.O. Box 2100, CH-1211 Geneva 2, Switzerland, [www.cioms.ch](http://www.cioms.ch), e-mail: [info@cioms.ch](mailto:info@cioms.ch).

This publication is freely available on the CIOMS website at: [https://cioms.ch/working\\_groups/principles-of-good-governance-for-research-institutions/](https://cioms.ch/working_groups/principles-of-good-governance-for-research-institutions/)

**Suggested citation:** International Guidelines on Good Governance Practice for Research Institutions. CIOMS Working Group report. Draft for comment, 12 April 2023. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS), 2022.

**Disclaimer:** The authors alone are responsible for the views expressed in this publication, and those views do not necessarily represent the decisions, policies or views of their respective institutions or companies.

# 1 TABLE OF CONTENT

2	TABLE OF CONTENT .....	3
3	LIST OF FIGURES, TABLES AND BOXES .....	6
4	ABBREVIATIONS AND ACRONYMS .....	6
5	GLOSSARY .....	7
6	FOREWORD.....	8
7	INTRODUCTION .....	8
8	BACKGROUND.....	11
9	STRUCTURE AND CONTENT.....	12
10	Chapter 1: Research Institution Management .....	14
11	Key words.....	14
12	Background and Principles .....	14
13	Points to consider and how to address them .....	14
14	1. Research Scope, Mission, Vision and Values .....	14
15	2. Organizational Structure, Leadership and Culture.....	14
16	3. Knowledge Management, Quality Management and Risk Management.....	16
17	4. Corporate Communications .....	18
18	References.....	19
19	Chapter 2: Ethics, Law and Scientific Integrity.....	20
20	Key words.....	20
21	Introduction.....	20
22	Points to consider and how to address them .....	20
23	5. Responsibilities towards research participants.....	20
24	6. Responsibilities towards researchers and research team members .....	22
25	7. Institutional culture to enhance working with scientific integrity .....	23
26	8. Accountability, transparency and participation .....	24
27	References.....	25
28	Chapter 3: Scientific standards.....	26
29	Key words.....	26
30	Background and Principles .....	26
31	Points to consider and how to address them .....	27
32	9. Awareness and coordination of proposed and ongoing research .....	27
33	10. Scientific value and appropriate research plan .....	28
34	11. Scientific rigor—review and training.....	29
35	References .....	30
36	Chapter 4: Collection, storage, and use of data and/or biological materials in health-related	
37	research.....	31

38	Key word .....	31
39	Background and Principles .....	31
40	Points to consider and how to address them .....	32
41	12. Responsibilities towards the participants .....	32
42	13. Access and transfer of data and biological materials .....	33
43	14. Biobank & Databank.....	34
44	15. Operational requirements for the collection, storage and use of data and biological	
45	materials .....	35
46	16. Data lifecycle .....	35
47	References .....	37
48	Chapter 5: Financial Management and Budgeting .....	38
49	Key words.....	38
50	Background and Principles .....	38
51	Points to consider and how to address them .....	38
52	17. Institutional Resources Planning.....	38
53	18. Project Budgeting .....	40
54	19. Financial Administration .....	42
55	20. Financial Compliance .....	43
56	References .....	44
57	Chapter 6: Collaboration .....	45
58	Key words.....	45
59	Background and Principles .....	45
60	Points to consider and how to address them .....	46
61	21. Identification of Suitable Collaborators.....	46
62	22. Collaboration Plan and Concerted Execution.....	47
63	23. Collaboration Agreements .....	48
64	References .....	49
65	Chapter 7: Communication.....	50
66	Background and Principles .....	50
67	Points to consider and how to address them .....	51
68	24. Internal communication .....	51
69	25. External Communication Plan .....	51
70	26. Institutional policies .....	53
71	References .....	54
72	Chapter 8: Education and Learning.....	55
73	Key words.....	55
74	Background and Principles .....	55
75	Points to consider and how to address them .....	56

76	27.	Basic Professional Qualifications.....	56
77	28.	Research Concepts, Standards and Skills.....	56
78	29.	Project-specific Requirements .....	57
79	30.	Institutional Governance of Qualifications and Learning .....	57
80		References .....	58
81		Chapter 9: Institutional Research Oversight .....	59
82		Key words.....	59
83		Background and Principles .....	59
84		Points to consider and how to address them .....	60
85	31.	Methods of Research Oversight .....	60
86	32.	Internal Research Oversight .....	61
87	33.	External Research Oversight.....	63
88	34.	Continuous Improvement.....	63
89		References .....	64
90		Annex: Points to Consider in Establishing Good Governance Practice for Research Institutions	
91		.....	65
92		Participants in the working group .....	67
93			
94			

## 95 LIST OF FIGURES, TABLES AND BOXES

96	<b>Figure 1:</b> Main Domains to Consider in the Good Governance Practice of Research Institutions	
97	.....	12
98	<b>Figure 2:</b> Biobank & Databank .....	34
99	<b>Figure 3:</b> Data lifecycle.....	36

100

101	<b>Table 1:</b> Example of matrix management .....	15
102	<b>Table 2:</b> The quality management cycle .....	16
103	<b>Table 3:</b> 6As risk management strategy for research institutions .....	17
104	<b>Table 4:</b> Summary checklist for research institutions to assure scientific standards.....	29
105	<b>Table 5:</b> Common cost types and cost items for research institutions.....	39
106	<b>Table 6:</b> Recurring and alternative resources available to research institutions .....	40
107	<b>Table 7:</b> Direct and indirect costs for research projects.....	41
108	<b>Table 8:</b> Budget structural categories and corresponding cost items for research projects .....	42
109	<b>Table 9:</b> Core domains of qualifications and learning for research personnel .....	57
110	<b>Table 10:</b> Overview of research oversight.....	60
111	<b>Table 11:</b> Outline of an internal research oversight system.....	61

## 112 ABBREVIATIONS AND ACRONYMS

113	<b>CRIS:</b> Clinical Research Information System
114	<b>DMP:</b> Data Management Plan
115	<b>DTA:</b> Data Transfert Agreement
116	<b>DMP:</b> Data Management Plan
117	<b>GCP:</b> Good Clinical Practice
118	<b>GGPRI:</b> Good Governance Practice for Research Institutions
119	<b>ICH-GCP:</b> International Council for Harmonisation of Technical Requirements for
120	Pharmaceuticals for Human Use (ICH) <i>Guideline for Good Clinical Practice</i> E6(R2). 2016
121	<b>IPA:</b> Intellectual Property Agreements
122	<b>MTA:</b> Material Transfert Agreement
123	<b>IRB:</b> Institutional Review Board
124	<b>LIMS:</b> Laboratory Information Management Systems
125	<b>NRA:</b> National Regulatory Authorities
126	<b>PI:</b> Principal Investigators
127	<b>PPIE:</b> Patient and Public Involvement and Engagement
128	<b>REC:</b> Research Ethics Committee
129	<b>SOP:</b> Standard Operating Procedure
130	...
131	

## GLOSSARY

**Health-related research:** activities designed to develop or contribute to generalizable health knowledge within the more classic realm of research with humans, such as observational research, clinical trials, biobanking and epidemiological studies. Generalizable health knowledge consists of theories, principles or relationships, or the accumulation of information on which they are based related to health, which can be corroborated by accepted scientific methods of observation and inference<sup>1</sup>.

**Governance:** The manner in which institutions exercise their power in the management of the organizational, human and infrastructure resources, directly or indirectly, dedicated to research activities. Governance includes mechanisms (structures, standards, procedures, strategies, processes etc.), both formal and informal, designed for the exercise of this power.

**Good governance:** Principles guiding research institutions in the responsible and efficient exercise of its power in conducting research activities in a way that fulfils its obligations and goals, as described in this tool, toward all research stakeholders, in particular the human participants, the researchers and the population.

**Good Governance Practice for Research Institutions:** A methodological tool describing good governance with the goal of helping research institutions to assess and improve the way they provide support to research stakeholders depending on their needs and according to their available resources. The purpose of the GGPRI is that each research institution is aware both of the research activities carried on within its infrastructures – or in relation with them - and of its responsibilities on that behalf, and adopts the appropriate level of governance of research depending on its needs and resources.

**Research institution:** Any public or private entity or agency or healthcare or public health facility where health-related research is conducted. For the purpose of this recommendation, the notion of research institution covers all facilities where health-related research activities are carried on regardless of whether research is explicitly recognized as part of their mandate or core business and is not limited to facilities primarily dedicated to health-related research (e.g. clinical trial centers).

**Research waste:** research outcomes that cannot be used or with no societal benefits.

**Resources** means time, training, qualified staff, facilities, clinical and laboratories equipment, hardware and software, communication tools, data protection infrastructure, health databases and biobanks, ethical and legal counselling, etc. This is not only a matter of financial support but also a question of governance: what services and supports are available for the researchers to meet their responsibilities as imposed by research ethics and regulation.

**Study data:** health related research data, internal clinical and/or research databank and biobank.

**terms to also define: Research participants / Research/ research project/ research infrastructure/ biobank/ repository**

*To be completed with key terms from 2022 CIOMS Cumulative Glossary and other documents of references (TRREE)*

---

<sup>1</sup> Council for International Organizations of Medical Sciences (CIOMS). *International ethical guidelines for health-related research involving humans*. 2016

## FOREWORD

### INTRODUCTION

Scientific research is essential for the protection and improvement of the health and well-being of the populations around the world<sup>2</sup>. Researchers are at the front line to respond to major crisis, such as the COVID-19 pandemic and the climate change, that impact everyone. More than ever, the scientific community bears heavy responsibilities to face those unprecedented challenges. COVID-19 vaccines development is a unique example of the success of its concerted actions in the health sector.

Since the 60s, research activities involving human participants has grown steadily with a trend toward globalization and industrialization. Health-related research has become highly complex with a wide range of stakeholders active at the local, regional and international levels. To facilitate and contain this process, numerous ethical, professional and industrial guiding documents have been adopted and constitute a dense normative framework. One of the first and most cited of those documents is the Declaration of Helsinki adopted in 1964<sup>3</sup> by the World Medical Association, largely recognized as the “Constitution” of research ethics and to which all other documents make references to, including the 2016 CIOMS International ethical guidelines for health-related research involving humans<sup>4</sup>.

Most ethical guidelines and laws focus on individual researchers’ responsibilities to protect the welfare, rights and dignity of research participants, Research Ethics Committees (REC) acting as gatekeepers. The 2016 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) *Guideline for Good Clinical Practice* E6(R2) (ICH GCP) is a noticeable exception as it provides detailed guidance on the responsibilities of the sponsors, covering governance, SOPs, quality-assurance and data management issues. Yet they are designed for drug trials, and they do not address the role of other stakeholders, such as patients’ organizations and the community, and research institutions, even if they are often used as a reference in other health-related studies than drug trials. Another interesting document of reference is the 2011 WHO Standards and Operational Guidance for Ethics Review of Health-Related Research with Human, but it mostly focuses on the responsibilities of entities establishing RECs, which in many countries are not research institutions. The Association for the Accreditation of Human Research Protection Programs (AAHRPP) should also be mentioned as an independent, non-profit organization, helping institutions to strengthen their human research protection programs through an accreditation process. Although it is mostly based on the US regulation according to which RECs or Institutional Review Boards (IRBs) are established by research institutions, numerous institutions are using them in 17 countries of which 10 in Asia.

In practice, it is rarely assessed to what extent researchers have the necessary resources in their institution to fulfil their responsibilities. This assessment is done separately for each protocol in absence of an agreed reference framework, with the consequence that there is often little information on the research activities and the resources available in each organization, hospital or healthcare facility to guarantee the protection of research participants and of their communities, and the quality of research.

<sup>2</sup> World Health Organization. *WHO Health Report: Research for universal health coverage*. 2013.

<sup>3</sup> World Medical Association (WMA) *Declaration of Helsinki – ethical principles for medical research involving human subjects*. 2013.

<sup>4</sup> Council for International Organizations of Medical Sciences (CIOMS) *International ethical guidelines for health-related research involving humans*. 2016.



211 In 2016, the World Medical Association included a section on governance in the Declaration of  
 212 Taipei on Ethical Considerations regarding Health Databases and Biobanks<sup>5</sup>. The 2016 CIOMS  
 213 Ethical Guidelines for Health-Related Research Involving Humans also addresses the issue of  
 214 governance for biobanks which is likewise included in the 2016 Council of Europe  
 215 Recommendation CM/Rec(2016)6 on research on biological materials of human origin<sup>6</sup>. This  
 216 illustrates a growing attention in research ethics on the necessary resources to conduct research  
 217 and on the governance of those resources.

218 Another key issue is the recognition of the diversity of communities with their specific needs and  
 219 identities which must be addressed in a more comprehensive way in health-related research. In  
 220 this perspective this is essential to acknowledge the intersectionality of potential disadvantage  
 221 based in particular on sex, race, ethnicity, gender identity, disability, migrant status, education or  
 222 class. In other words, that “all forms of inequality are mutually reinforcing and must therefore be  
 223 analysed and addressed simultaneously to prevent one form of inequality from reinforcing  
 224 another.”<sup>7</sup>

225 Addressing the challenge of promoting health equity in research ethics, and in line with the  
 226 conceptual work on vulnerability in the 2016 CIOMS Ethical Guidelines, other important  
 227 documents of references have been adopted recently focusing on the equitable use of existing  
 228 resources, while promoting collaboration and participation of all stakeholders, such as the 2015  
 229 FAIR Guiding Principles for scientific data management and stewardship<sup>8</sup>, the 2018 Global Code  
 230 of Conduct for Research in Resource Poor Settings<sup>9</sup> and the 2021 CIOMS Consensus on Clinical  
 231 research in resource-limited settings<sup>10</sup>. Moving away from the paternalistic vision that research  
 232 participants are primarily defined by their vulnerability and their need to be protected, those  
 233 documents are based on a more egalitarian perspective that research participants and their  
 234 communities should also be considered as – and treated like – co-creators of the research they  
 235 are involved in. This calls for a change in the way their participation is organized, and their opinion  
 236 be heard from the conception of research projects to the dissemination of their results.

237 This shift of paradigm creates an urgent need to better recognize the essential role of institutions  
 238 in which – or in relation with – research is conducted. The current guidelines are meant to fill up  
 239 the gap in the normative framework of health-related research involving human participants with  
 240 the aim to help research institutions by offering a proper environment for the researchers to meet  
 241 with their ethical and professional responsibilities. They are grounded on the vision that institutions  
 242 should not be ignoring or covering up unethical research activities but should rather stand for the

---

<sup>5</sup> World Medical Association (WMA) *Declaration of Taipei – ethical considerations regarding health databases and biobanks*. 2016.

<sup>6</sup> Council of Europe (COE) *Recommendation CM/Rec(2016)6 of the Committee of Ministers to member States on research on biological materials of human origin*. 2016.

<sup>7</sup> <https://www.intersectionaljustice.org/what-is-intersectionality> (last consulted on April 6, 2023)

<sup>8</sup> Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten JW, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O, Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJ, Groth P, Goble C, Grethe JS, Heringa J, 't Hoen PA, Hooft R, Kuhn T, Kok R, Kok J, Lusher SJ, Martone ME, Mons A, Packer AL, Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone SA, Schultes E, Sengstag T, Slater T, Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A, Wittenburg P, Wolstencroft K, Zhao J, Mons B. *The FAIR Guiding Principles for scientific data management and stewardship*. Sci Data. 2019 Mar 19;6(1):6. PMID: 26978244; PMCID: PMC4792175.

<sup>9</sup> Schroeder, Doris & Chatfield, Kate & Cook, Julie & Wynberg, Rachel & Chennells, Roger & Cavallaro, Francesca & Niekerk, Jaci & Norton, David & Coles, David & Andanda, Pamela & Woodgate, Paul. (2018). *Global Code of Conduct for Research in Resource-Poor Settings*. 10.13140/RG.2.2.19106.27848.

<sup>10</sup> Council for International Organizations of Medical Sciences (CIOMS) Working Group report: *Clinical research in resource-limited settings*. 2021.

243 principles of research ethics as part of their social contract and implement the highest ethical,  
244 legal, professional and scientific standards in the field of health-related research.

245 The aim of those guidelines is to help research institutions better fulfill their responsibilities in terms  
246 of protecting human research participants and their communities, by involving and engaging them  
247 in the research processes and by guaranteeing the pertinence and quality of research while  
248 making best use of their available resources. Those guidelines offer research institutions a  
249 detailed and specific guidance on how to implement the existing ethical and professional  
250 standards. They are complementary to the provisions on governance that have been introduced  
251 in the most recent documents of reference as well as in the ICH-GCP.

252 **None of the following chapters are creating new obligations for research institutions.** First,  
253 the institutions' responsibilities are derived from their general obligation toward their patients and  
254 the populations they care for, but also linked to the fact institutions may be employers of the  
255 researchers or potential sponsor of their researchers as they are supporting and financing them,  
256 knowingly or not. Second, they are defined by existing guidelines and regulations concerning  
257 health-related research involving human participants at the local, national and international levels.  
258 The current guidelines do not modify the liability of research institutions by setting new standards.  
259 They only intend to clarify the existing rules and help institutions better cope with them.

260 Institutions contribute to health-related research for instance through the participation of their  
261 patients, or their employees or both, in research, surveys or questionnaires on health-related  
262 issues helping to develop or contribute to generalizable health knowledge, or by authorizing  
263 sharing health data and biological material with researchers within or outside the institution.  
264 Concerning the further use of health data and biological material for research purposes, it can be  
265 done in any healthcare or public health facility collecting such data and material. In fact, many  
266 studies are not carried on in dedicated research centers but in public or private healthcare centers,  
267 hospitals, day care or home care facilities or in public health services.

268 Having research carried on in - or in relation with - an institution involves some degree of  
269 responsibilities for that institution even when an external sponsor is driving the study. Public or  
270 private entities or institutions are legally and ethically responsible and accountable for the health-  
271 related research they conduct or sponsor, for fulfilling their obligations and responsibilities not only  
272 towards their own mission, and also for the human participants, researchers, population at large  
273 and any other research stakeholders. This includes protecting the welfare, rights and dignity of  
274 the participants, but also their employees' rights and scientific freedom, in a sustained way and  
275 with respect for the environment. Even when research activities remain at a low level, they raise  
276 issues in terms of research ethics, public health and scientific integrity. Yet, this is neither  
277 necessary nor desirable to create clinical research centers in most institutions. What is essential  
278 is that each research institution is aware of the activities carried on within – or in relation with – its  
279 infrastructures and adopts the appropriate level of governance depending on its needs and  
280 resources.

281 In many institutions in which – or in relation with – research is conducted, there is limited attention  
282 paid to research by the management. The first reason is obviously that research is simply not part  
283 of their mission. Yet, for physicians and healthcare professionals, research is essential to address  
284 the needs of their patients and is, therefore, an ethical and professional obligation. For physicians  
285 and other healthcare providers it can also have an important impact on their careers and academic  
286 recognition. Those guidelines can thus also be used by researchers themselves to engage in a  
287 dialog with their institutions while addressing broader issues in terms of governance, quality-  
288 assurance and control or patients' safety and involvement. Commercial sponsors and funding  
289 agencies could also consider referring to them when implementing their research projects at the  
290 institutional level.

By raising the awareness of research institutions to the above-mentioned issues, the aim is to provide them with a tool to better benefit from research activities while limiting the diversion of resources needed for healthcare and public health interventions. Implementing those guidelines requires first and foremost (1) to identify the current and planned research activities being conducted within – or in relation with - it and evaluating the main issues at stake. Based on this assessment, (2) the next step is to map the existing resources used for research and how they are integrated in the primary mission of the institution. Having completed this mapping or while doing it, (3) a strategy could be designed to improve coordination of research activities for the benefit of the institution's overall activities. In most instances, research strategy should not be defined in isolation but in relation with broader strategies related to improving the efficiency of the institution, quality-assurance and quality control as well as patients' safety and involvement. (4) This can be done in a participatory process with all the professionals in the institutions, the patients and the population. There is a direct link between research, quality of care and the capacity of institutions to respond to the health needs of the population<sup>11</sup>. Including research activities in the management of the institution's resources is therefore beneficial for all the other activities of the concerned institutions.

## **BACKGROUND**

The Council for International Organizations of Medical Sciences (CIOMS) is an international, non-governmental, non-profit organization established jointly by WHO and UNESCO in 1949. CIOMS mission is to advance public health through guidance on health research including ethics, medical product development and safety.

CIOMS reports are in-depth guidance documents which serve as worldwide references and guidance for specific subject matters. In addition to the revised 2016 CIOMS International Ethical Guidelines for Health-Related Research Involving Humans, CIOMS Working Groups have published in 2021 a Consensus Report on Clinical research in resource-limited settings<sup>12</sup> and a 2022 Report on Patient involvement in the development, regulation and safe use of medicines.<sup>13</sup>

As a unique global and scientific organization, CIOMS is well positioned to develop a multi-stakeholders' international guidelines on the good governance practice for research institutions. A Working Group was mandated by CIOMS Executive board to address the issue building on existing ethical and professional guiding documents as well as the current regulation at the national, regional and international levels. The main task is to target institutions which do not consider research as part of their primary mission in order to improve their capacities in the field by offering an appropriate environment for their researchers to conduct their activities according to the high standards in research ethics and regulation.

The starting point of CIOMS Working Group in charge of drafting those guidelines on Good Governance Practice for Research Institutions has been to identify the various resources needed to realize research projects. "Resources" here means time, training, qualified staff, facilities, clinical and laboratories equipment, hardware and software, communication tools, data protection infrastructure, health databases and biobanks, ethical and legal counselling, etc. It is not only a matter of financial support but more of a governance question, in other words, what services and supports are necessary for researchers to meet their responsibilities as imposed by research ethics and regulation.

<sup>11</sup> World Health Organization. *WHO Health Report: Research for universal health coverage*. 2013.

<sup>12</sup> Council for International Organizations of Medical Sciences (CIOMS) Working Group report: *Clinical research in resource-limited settings*. 2021.

<sup>13</sup> Council for International Organizations of Medical Sciences (CIOMS) Working Group report: *Patient involvement in the development, regulation and safe use of medicines*. 2021.


## 333 **STRUCTURE AND CONTENT**

334 To facilitate their understanding and use, those guidelines have been divided in twelve domains  
335 into which institutions should pay attention, namely:

- 336 ○ Management
- 337 ○ Ethics
- 338 ○ Law
- 339 ○ Research integrity & Conflict of interests
- 340 ○ Scientific standards
- 341 ○ Collection, storage and use of data and biological materials:
  - 342 ■ Biobanks & Registries
  - 343 ■ Data Handling & Information Technology (IT)
- 344 ○ Budget & Financing
- 345 ○ Collaboration
- 346 ○ Communication
- 347 ○ Education & Training
- 348 ○ Institutional research oversight

349 Each domain encompasses various resources that can be subdivided in terms of infrastructures,  
350 human resources and organizational resources. Those resources should already be available in  
351 all research institutions, especially concerning the infrastructure and human resources being used  
352 for research, but not necessarily under the explicit control and supervision of the institutions  
353 themselves. Improving the good governance of research in each domain is an efficient way of  
354 making a better use of those resources. Each domain is equally important depending on the  
355 circumstances.

357 **Figure 1: Main Domains to Consider in the Good Governance Practice of Research Institutions**





361 In general, there is one chapter per domain, but some domains have been merged in a single  
362 chapter as they are treated so closely in practice that researchers are used to deal with them  
363 together. Each chapter should be interpreted and read at the light of the others, and not in  
364 isolation.

365 Research involving human beings is a highly complex activity operating under numerous  
366 constraints and a detailed regulatory framework. This explains why some chapters are more  
367 detailed and technical than others, as this is only reflecting the domain it addresses such as IT or  
368 biobanking. This technicality cannot be ignored. This is especially true in the field of drug trials  
369 since many tend to consider them as the gold standard in biomedical research with human  
370 participants. Although the importance of the ICH-GCP in research practice cannot be diminished,  
371 it is also true that in many research fields, such as behavioral research, observational studies or  
372 qualitative studies, they are not adapted/appropriate. In some instances, their implementation  
373 could even be detrimental to both the protection of research participants and the quality of  
374 research.

375 Each chapter includes a list of key words, the background and the applicable principles, as well  
376 as the main points to consider in the given domain and how to address them. There is also a list  
377 of documents of references creating the link with the existing normative framework of research  
378 involving human participants. The points to consider are also listed in annex as a tool for the  
379 research institutions to map research activities and available resources but also as a tool to follow  
380 up the progress being made to reinforce the good governance practice of research in the  
381 institutions.

382

383

## Chapter 1: Research Institution Management

### Key words

*Accountability – Compliance – Corporate communications – Corrective actions and preventive actions – Delegation – Dimensions of management – Discrimination – Harassment – Integrity – Knowledge management – Leadership – Learning organization – Matrix management – Mission, Organizational culture – Organizational structure – Quality management – Risk management – Social responsibility – Sustainability – Transparency – Trust – Value – Vision – Whistle-blowing*

### Background and Principles

Research institutions, like any other enterprises and organizations, exist for a specific social purpose. The three “**dimensions of management**” for any organization are:

- defining the specific purpose and mission of the organization;
- making work productive and the workers achieving;
- managing social impacts and social responsibilities.

Good governance for research institutions – that relies on corporate ethics, compliance, transparency and public accountability – should be built on four core management elements including:

- defined research scope, mission, vision and values;
- effective organizational structure, leadership and culture;
- robust knowledge management, quality management and risk management;
- corporate communications.

### Points to consider and how to address them

#### *1. Research Scope, Mission, Vision and Values*

Research institutions are of a wide diversity in their business scopes. While some may be academic research institutions engaging in a full spectrum of research areas ranging from interventional clinical trials on novel medicinal products to non-interventional health-related studies (e.g. university hospitals, clinical trial centers), others may have their main business in areas other than research (e.g. hospitals and healthcare facilities providing clinical services) and some may also allocate part of their time and resources to support health-related research projects with particular interest (e.g. patients-oriented outcomes research, pediatrics research). Each research institution should therefore, considering its core business, direction and corporate social responsibility, define its research mission, vision and values in alignment with its scope of research. Clear research scope, mission, vision and values are of paramount importance to a research institution as they set the ground for:

- formulating its organizational structure, personnel composition, resource plans and development strategies;
- designing its facilities and infrastructures, operational workflow and technology applications;
- attracting qualified professionals and guiding their professional conduct and behaviors.

#### *2. Organizational Structure, Leadership and Culture*


Health-related research is knowledge-based, multidisciplinary, dynamic, forward-looking whilst practical. To respond to its needs in research based on its available resources, a research institution should build up an organizational and human infrastructure with:

- leaders interested in research and empowered to undertake ethical leadership in driving the management and development of the research institution;
- a suitable mix of diversified professionals that together cover the research institution's scope of research, with well-defined roles and relationships which facilitate effective teamwork among the members and support efficient delivery of research outputs;
- an ethical culture that facilitates the productive execution of the institution's research activities – both at organizational and individual levels – and supports the accomplishment of the institution's social responsibilities and social impacts.

Understanding of health-related research adds value to research institution leadership. However, the motivation and vision for accomplishing an institution's mission and social responsibility via research may be of even higher importance to effective leadership. A research institution leader should therefore be motivated to appreciate research ethics and compliance standards, and should possess professional management skills, in particular in attracting, retaining and growing suitable professionals, facilitating teamwork and resolving conflicts and dilemmas. With due respect to the importance of science, leaders of research institutions do not necessarily need to be top scientists.

Effective teamwork starts from clear delegation of job roles, definition of lines of reporting/collaboration and allocation of responsibilities, which should be illustrated on a clear organizational chart and outlined on the corresponding written job descriptions. Modern organizations in dynamic industries, such as research institutions, may adopt a “**matrix management**” approach where a functional specialist may report to a functional team leader and to several project team leaders at the same time in order to enhance open and efficient cross-functional communication necessary for multidisciplinary collaboration.

**Table 1: Example of matrix management**



Organizational culture refers to a set of shared assumptions and norms that guide the behavior of an organization's members. An ethical culture in workplace is the base for effective management and teamwork for sustainable organization. Research institutions should therefore strive to build an ethical culture by securing the core ethical principles at work through developing and enforcing relevant codes of conduct, on:

- social value and social accountability;
- ethical, legal and quality compliance;
- transparency, integrity and whistle-blowing;
- equal opportunity (including but not limited to cultural diversity and pluralism, non-discrimination of minorities and vulnerable groups, and intolerance of sexual or other types of harassment);
- maintaining an inclusive and unbiased approach to staffing, and appoints research staff keeping gender balance in mind;
- promoting, and supporting the principle of gender inclusivity and equity throughout the research cycle;
- respect, open mindedness, open communication and collaboration;
- continuous learning;
- occupational health and safety.

### 3. *Knowledge Management, Quality Management and Risk Management*


A research institution could only achieve its objectives through continuous accumulation of knowledge and experience – which may take times. This means that a research institution should facilitate not only contemporaneous collaboration among staff members working together at the same time but also cross-generational collaboration for members who worked for the institution at different time. Robust “**knowledge management**”, “**quality management**” and “**risk management**” are therefore the key for sustainable research institutions.

Knowledge management is the way to collect, organize and retain information and knowledge in a retrievable and usable manner. Good knowledge management supports the efficient and effective acquisition, accumulation, organization, processing, utilization and sharing of professional knowledge and experience – among staff members and over time – and facilitates innovation and development of a research institution as a “**learning organization**” able to evolve continuously to meet its changing research needs and operate with long-term sustainability. Knowledge management may be powered by an adaptive information technology system, but should more importantly be built on a learning culture signified by open exchange, sharing and proactive learning, as well as continuous improvement with the support of a robust quality management system.

Quality is a cornerstone of health-related research. A quality management system is a continuous cycle consisting of four components including:

- **quality planning and standard establishment:** identifying or defining applicable quality standards and establishing suitable policies and standards operating procedures (SOPs) (e.g. establishing institutional policies mandating research ethics and scientific oversight by a research ethics committee appointed by the research institution);
- **execution of quality standards:** training of staff and continuing monitoring of performance (e.g. providing training on updated concepts and requirements on health-related research);
- **quality evaluation:** regular and systematic evaluation of performance

**Table 2: *The quality management cycle***





(e.g. establishing a quality control mechanism and performing quality control regularly and as needed);

- **quality improvement:** undertaking corrective actions and preventive actions in response to any quality issues identified, including escalation to senior management and research ethics committee, and adjusting quality standards and quality plans to support continuous improvement (e.g. classifying quality issues based on the nature and level of impact and prescribing appropriate corrective and preventive actions).

Any research institution aiming at continuing involvement in health-related research is recommended to establish an operable quality management system meeting its research needs. Robust quality management also helps an institution to control its risk and attain long-term sustainability.

Research is a process of discovering new knowledge. This unavoidably involves uncertainty and hence some risks. Health-related research relies on the willingness of research participants and the public, involves utilization of scarce (public and private) research resources, and is subject to stringent compliance requirements. Any research institution therefore should consider at least three main areas of risk including:

- **participant risk:** risk on protecting the rights, safety and well-being of research participants and the related communities;
- **compliance risk:** risk on ethical, legal and quality compliance;
- **resource risk:** risk on appropriate acquisition and utilization of research resources.

Research institutions should not be afraid of risks provided that those risks are well known and are under control. Whilst risks may not be fully eliminated, they could be effectively managed by applying the “**6As risk management strategy**” as outlined in Table 3 below.

**Table 3: 6As risk management strategy for research institutions**

Risk Management Strategy		Examples of Risk Management Measures
Alert	Identifying risks and communicating with the relevant stakeholders	<ul style="list-style-type: none"> <li>• Identifying risks through scientific and ethical review</li> <li>• Communicating risks with research participants via informed consent</li> </ul>
Abate	Minimizing the likelihood (probability) of risk occurrence	<ul style="list-style-type: none"> <li>• Implementing public involvement in research design and arrangements</li> <li>• Enhancing research competence of research personnel via training and learning</li> <li>• Implementing a robust quality management system</li> </ul>
Alleviate	Minimizing the consequence (harm) of risk occurrence	<ul style="list-style-type: none"> <li>• Implementing continuing oversight of research activities to facilitate early detection of risk occurrence (e.g. establishing safety monitoring committees for research projects of higher safety risk)</li> <li>• Implementing a complaint management mechanism and a contingency management mechanism to facilitate prompt handling of risk occurrence</li> </ul>
Assign	Transferring risks to third parties	<ul style="list-style-type: none"> <li>• Transferring risks by insurance/indemnity to insurers/indemnifiers</li> <li>• Allocating risks appropriately by written contracts among collaborating parties</li> </ul>
Accept	Accepting identified risks	<ul style="list-style-type: none"> <li>• Accepting identified and controlled risks by allocating sufficient resources and implementing an appropriate risk management mechanism</li> </ul>

Abandon	Giving up research activities with unacceptable risks	<ul style="list-style-type: none"> <li>• Giving up research activities with unacceptable risk</li> <li>• Making substantial modifications to research projects to bring their risk to an acceptable level</li> </ul>
---------	---	--

528

529

#### 4. Corporate Communications

530

531

532

533

534

Health-related research is people-oriented, since it is performed by people (e.g. researchers, research institution personnel and sponsors), with people (i.e. research participants) and for people (i.e. patients and public). Research institutions are therefore accountable to the public, in particular the key stakeholders, and has the responsibility to properly communicate their research activities, results and outputs to them in a timely manner.

535

536

537

Corporate communications refer to the way an organization communicate with its internal and external stakeholders. With respect to a research institution, key stakeholders include (but not limited to):

538

539

540

541

542

543

544

545

- research participants;
- patient groups;
- the general public and media;
- research ethics committees and regulatory agencies;
- professional scientific associations/organizations/networks;
- research project sponsors;
- funding bodies; and
- researchers, research personnel and supporting staff.

546

547

Corporate communications are not only about disclosure of research results. They should be taken as a part of a research institution's organizational strategy and bring important value including:

548

549

550

551

552

553

554

555

556

557

558

559

560

561

- **social responsibility and social impacts:** fulfilling an institution's social responsibility of research transparency and accountability and communicating the social impacts;
- **public awareness and trust:** increasing public awareness and trust, and their support on health-related research;
- **patient/public focus:** aligning research focus with the needs of patients/public and improving research design through patient/public participation;
- **research participants involvement:** involving the participants in research projects and activities;
- **scientific exchange:** accelerating research by sharing of research methods and results via publication and public disclosure;
- **research collaboration:** encouraging research collaboration among research institutions;
- **funding:** attracting research funding and resources;
- **staff commitment:** promoting staff's commitment to the institution's mission, vision and values and improving the institution's performance, sustainability and long-term success.

562

563 **References**

- 564 Drucker, Peter F.: *The Dimensions of Management*. In Management (Revised ed., pp. 26-33).  
 565 New York: Collins Business, 2008.
- 566 Drucker, Peter F.: *Strategies and Structures*. In: Management (Revised ed., pp. 407-426). New  
 567 York: Collins Business, 2008.
- 568 Gottlieb, Marvin R.: *The Matrix Organization Reloaded: Adventures in Team and Project*  
 569 *Management*. Westport: Praeger Publishers, 2007.
- 570 German Research Foundation: *Guidelines for Safeguarding Good Research Practice. Code of*  
 571 *Conduct*. Bonn, 2019. Status: November 2021 / revised version 1.1. URL  
 572 [https://www.dfg.de/download/pdf/foerderung/rechtliche\\_rahmenbedingungen/gute\\_wissenschaftl](https://www.dfg.de/download/pdf/foerderung/rechtliche_rahmenbedingungen/gute_wissenschaftliche_praxis/kodex_gwp_en.pdf)  
 573 [iche\\_praxis/kodex\\_gwp\\_en.pdf](https://www.dfg.de/download/pdf/foerderung/rechtliche_rahmenbedingungen/gute_wissenschaftliche_praxis/kodex_gwp_en.pdf).
- 574 Schwartz, Mark S.: *Developing and Sustaining an Ethical Corporate Culture*. The Core Elements.  
 575 In: Business Horizons. 56 (2013), 1, 39-50. DOI [10.1016/j.bushor.2012.09.002](https://doi.org/10.1016/j.bushor.2012.09.002).
- 576 Lawton, Alan / Rayner, Julie / Lasthuizen, Karin (ed.): *Ethics and Management in the Public*  
 577 *Sector*. London, New York: Routledge, 2012. DOI [10.4324/9780203094129](https://doi.org/10.4324/9780203094129).
- 578 ISO 31000:2018. *Risk management — Guidelines*. International Organization for Standardization.  
 579 URL <https://www.iso.org/obp/ui/#iso:std:iso:31000:ed-2:v1:en>

580

## 581 Chapter 2: Ethics, Law and Scientific Integrity

### 582 Key words

583 *Obligations – Rights – Responsibilities – Scientific freedom – Scientific integrity – Social license –*  
 584 *Scientific culture*

### 585 Introduction

586 Health-related research raises a wide range of ethical and legal challenges. In this chapter we will  
 587 describe the responsibility of institutions to create an environment where people adhere to the  
 588 principles described below. If national laws use a description of biomedical research that narrows  
 589 research to drug clinical trials, we urge the institutions performing research to follow the broader  
 590 definition of health-related research used in this guideline, in the 2013 Declaration of Helsinki, the  
 591 2016 Declaration of Taipei and the 2016 CIOMS International ethical guidelines.

592 First, there are issues related to the **protection of research participants**: respect for autonomy  
 593 of participants and for their dignity, fair inclusion of populations, protection of vulnerable  
 594 populations, respect of privacy and confidentiality, informed consent, favorable balance between  
 595 the risks and the benefits, choice of comparators, compensation in case of research related  
 596 damages, etc.

597 Second, the **rights of the researchers and scientific freedom must be respected**. This  
 598 includes having access to the necessary resources, having limited barriers to publish and share  
 599 research data and results, being protected from negative external pressures (financial,  
 600 professional and academic), etc.

601 Third, the **scientific integrity of research activities must be guaranteed**. This not only requires  
 602 managing conflicts of interests, preventing and addressing the occurrence of scientific  
 603 misconducts but it also creates a culture in which more emphasis on the social value of research  
 604 can flourish.

605 Fourth, regardless of their statutes and whether research is part of their mandate or core business,  
 606 **research institutions are accountable to research participants and populations** whose trust  
 607 is indispensable/essential to ensure participation in - and support for - research. This implies  
 608 working in transparency, co-creation in research, communicating about research activities and  
 609 thus earning the trust and social license to operate from patients, communities and the public in  
 610 order to be able to continue scientific research.

611 In many research institutions, the task to cope with all those complex ethical and legal issues lies  
 612 on the shoulders of the individual researchers. Yet, the research institutions have their own  
 613 responsibilities - first towards research participants who also are patients or key stakeholders in  
 614 those institutions, and then/second, towards the researchers themselves as their employees or  
 615 service providers/consultants. At least, their responsibilities should be carefully assessed to  
 616 manage liability risks if something goes wrong in a research project.

### 617 Points to consider and how to address them

#### 618 *5. Responsibilities towards research participants*

619 Research institutions are responsible to ensure that research participants rights are respected  
 620 because these institutions function either as employers of the researchers or as research sponsors  
 621 when there is no external sponsor (funding agencies, foundations, industry). In most countries,  
 622 institutions are not allowed to waive their responsibilities. This means they should implement  
 623 oversight mechanisms over research activities conducted by their employees or within their  
 624 infrastructure – or in relation with them – , ensuring that researchers act according to the applicable

ethical, legal, professional and scientific standards and that the welfare, rights and dignity of the participants are guaranteed. The level of scrutiny depends on the nature and the intensity of research activities and the level of risks for the participants, the community and society at large. The more intense the research activities are and the higher the risks are for the participants, the higher is the interest in research institutions to set up the necessary mechanisms to fulfill their obligations to limit the risks and manage the consequences or research induced damages (see Chapter 9: Institutional Research Oversight).

Special attention should be given to:

- Assuring that employees, collaborators and partners involved in research as investigators or member of research teams have the required education, training and expertise according to the applicable standards and law;
- Ensuring that researchers and research team members are gender balanced and belong to diverse ethnic groups that are representative of the research populations under study;
- Ensuring that research projects are submitted to the competent research ethics committee (REC) and competent authorities for review and that no project starts without prior approval/positive opinion of the competent REC and competent authorities when required by law. For that purpose, establishing a register of research proposals with their status (submitted, approved, on-going, ended) and tracking this at a central level is important;
- When there are more than one REC operating within the research institution or in relation with it, providing clear guidance to researchers to which REC they must submit any given project and preventing any form of “forum shopping”;
- When by law a project should not be reviewed not only by the competent and relevant REC, but also by other committees such as biosafety board or resource management committee, ensuring that researchers are informed about their obligation and providing them with clear guidance on the procedure to follow;
- Ensuring that all required contracts and agreements (e.g. Material Transfer Agreements, Data Sharing Agreements or Intellectual Property Agreements) are adequate and signed to protect the participants as well as the interests of the researchers and the institution;
- Ensuring that any documents including contracts:
  - Are compliant with the information and consent form;
  - Provide for care for participants’ health needs while participating in research in accordance with applicable law (cf. 2016 CIOMS International ethical guidelines, Guideline 6<sup>14</sup>);
  - Provide for participants access to medical care and compensation in case of damages suffered while participating to research, in accordance with applicable law;
  - Do not limit the communication of any new information of interest to participants.
- Following up in case of complaints about research misconduct.
- Ensuring that personal data and biological material are handled with respect to the applicable principles, including privacy, confidentiality, and global justice. Making sure that the institution provides substantial support to the researchers to assess the required level of data safety as well as ethical and legal counsel to meet those requirements (see Chapter 4: Collection, storage, and use of data and/or biological materials in health-related research).

<sup>14</sup> Council of Europe (COE) *Recommendation CM/Rec(2016)6 of the Committee of Ministers to member States on research on biological materials of human origin*. 2016.



## 6. Responsibilities towards researchers and research team members

The first responsibility of institutions towards researchers and research teams' members is to provide them the necessary support so they can fulfill their responsibilities towards research participants and respecting the quality standards of research. Therefore, all measures aiming at respecting the rights of research participants should be considered as protecting and supporting the researchers and the research teams' members as well. However, researchers also need specific support to protect their interests in terms of scientific freedom and integrity. These responsibilities are also reflected in the 2017 UNESCO recommendation on science and scientific researchers<sup>15</sup>

Special attention should be given to:

- Defending scientific freedom in the negotiation and conclusion of research agreements and all other contracts related to research activities. This includes warranting that researchers, in the respect of participant's rights, keep control over the design of their projects, over the collected data and biological material, over the research analysis and the publication. Any limitation to the right to publish results, either positive or negative depending on the research primary and secondary outcomes, should be carefully assessed to guarantee that it is limited in time and that all results could be published within a reasonable time.
- Providing ethical or legal support and counselling to researchers for issues that may raise in the drafting, evaluation, conduct, analysis and publication of research projects. This could take the form of giving access to the institution's ethical and legal resources, by offering resources to seek legal counselling on specific issues, such as liability, and by providing some legal support in relation with the conclusion of the various agreements related to the conduct of research projects, for instance by making agreements templates available.
- Create conditions for meaningful engagement and participation in the full cycle of a research project, as well as capacity building and contributions towards research outputs. Research participants, patients and local communities should be included throughout the research process from planning through post-study feedback and evaluation.
- In research partnerships where researchers are operating in limited-resources settings, additional care should be granted to guarantee that the local researchers benefit from the same freedom and protection as their colleagues from high income settings, for instance by securing their rights in research agreements and research funding agreements.
- Institutions are encouraged to provide research management, financial risk management and forecasting as well as administrative and legal support.
- Assessing research agreements. This at least implies:
  - o Advising researchers on their capacity to sign or not to sign an agreement on behalf of the institution.
  - o Assessing whether those contracts respect the applicable laws in terms of protecting the participants and the interests of the researchers and the institution.
  - o Developing templates for agreements (or using existing ones at the local, professional or national levels) and signing umbrella agreements with partner institutions and stakeholders with whom there are regular collaborations in terms of research activities and exchanges of personal data and biological material.

<sup>15</sup> United Nations Educational, Scientific and Cultural Organization (UNESCO), *Recommendation on Science and Scientific Researchers*. 2017.

## 7. *Institutional culture to enhance working with scientific integrity*

In a lot of scientific environments there still is a culture which can be described as 'publish or perish'. That culture has put scientific integrity under stress and has let the scientific community to produce a lot of research waste (Lancet series 2014) (see Chapter 3: Scientific standards), which has produced results that are hard to replicate and brings hardly any social value. In such a culture of 'publish or perish' the likelihood of scientific misconduct increases with detrimental consequences.

The countermovement is visible under different headings (e.g. Open Science, Responsible Research and Involvement, Science in transition) and puts much more emphasis on the quality, usability and social value of research and less emphasis on H-index and on Citation Indexes of journals. It should be noted that Open Science does not only mean publishing in Open Access journals, but also means open to society during all research phases.

Another aspect of scientific culture centers around hierarchy. Although clear communication lines are beneficial for an efficient conduct of a research project (see Chapter 1: Research Institution Management), it must be underlined that a strict hierarchy may contribute to an atmosphere in which conflicts of interest could flourish and scientific misconduct could occur. It is essential for researchers to operate from a stance that the other person could be right; to allow counterarguments; to acknowledge that reigning paradigms may be wrong and that new creative ideas help to bring a field forward. Hence it is important to create a safe atmosphere in institutions that perform research in which scientific creativity can flourish.

Scientific knowledge is a source of hope and of dispute in times of uncertainties. It requires trust from the public but also within the scientific community at the local, national and international levels. Research institutions have a responsibility in maintaining and fostering that trust as they are directly affected when it is questioned or lost, and also because it impacts trust in the larger scientific enterprise. A breach of scientific integrity, either by a researcher or by the research institution, can affect the participants' welfare, rights and dignity but also the capacity of research institutions to fulfil their mission beyond the research field.

According to the 2016 CIOMS International ethical guidelines (Guideline 25<sup>16</sup>) research institutions, researchers and research ethics committees should take the following steps:

- Research institutions should develop and implement policies and procedures to mitigate conflicts of interest and educate their staff about such conflicts;
- Researchers should ensure that the materials submitted to a research ethics committee include a disclosure of interests that may affect the research;
- Research ethics committees should evaluate each study in light of any disclosed interests and ensure that appropriate means of mitigation are taken in case of a conflict of interest; and
- Research ethics committees should require their members to disclose their own interests to the committee and take appropriate means of mitigation in case of a conflict of interest.

Special attention should be given to:

- Setting up internal procedures or guidelines addressing conflicts of interests and scientific misconducts and protecting whistleblowers;

---

<sup>16</sup> Council of Europe (COE). *Recommendation CM/Rec(2016)6 of the Committee of Ministers to member States on research on biological materials of human origin*. 2016.

- Ensuring access to training on those issues at all levels, starting with undergraduate education institutions and including all personnel potentially involved in research activities (see also UNESCO 2017<sup>17</sup>) including Research Ethics Committee members<sup>18</sup>;
- Adhering to anti-bribery laws;
- Offering researchers the necessary legal support especially for research with external partners.

## 8. Accountability, transparency and participation

Research institutions rely on the potential participants and the population to conduct research activities. This requires a high level of trust that can only be achieved when acting in an accountable and transparent way including some level of participation of all stakeholders, especially the research participants, patients, and the population.

Special attention should be given to:

- assuring that research activities are included in the annual report and subject to question by the competent organs/units/committees of the institution and the general public.
- Reporting to clinical trial registries or similar research registries (where applicable) and/or making information available on the website of the institution (where available), so that information about research can become available also in ICTRP (<https://www.who.int/clinical-trials-registry-platform>).
- Defining procedures that allow patients, research participants and the general public to be involved in defining research priorities and in the drafting of research strategies or research projects.
- Including patients, participants or their representatives in the organs/units/committees of the institution, if possible, with decision power.

<sup>17</sup> United Nations Educational, Scientific and Cultural Organization (UNESCO), *Recommendation on Science and Scientific Researchers*. 2017.

<sup>18</sup> World Medical Association (WMA) *Declaration of Helsinki – ethical principles for medical research involving human subjects*. 2013



780 **References**

- 781 Council for International Organizations of Medical Sciences (CIOMS) *International ethical*  
782 *guidelines for health-related research involving humans*. 2016
- 783 Council for International Organizations of Medical Sciences (CIOMS) Working Group report:  
784 *Clinical research in resource-limited settings*. 2021
- 785 European Federation of Academies of Sciences and Humanities (ALLEA). *The European Code of*  
786 *Conduct for Research Integrity*. 2017
- 787 *Global Code of Conduct for Research in Resource-Poor Setting*. 2018
- 788 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for  
789 Human Use (ICH) *Guideline for Good Clinical Practice E6(R2) (ICH GCP)*. 2016
- 790 UNESCO, *Universal Declaration on Bioethics and Human Rights*. 2005
- 791 UNESCO. *Recommendation on science and scientific researchers*. 2017
- 792 WHO Global guidance framework for the responsible use of the life sciences: mitigating biorisks  
793 and governing dual-use research <https://www.who.int/publications/i/item/9789240056107>
- 794 WHO *Standards and Operational Guidance for Ethics Review of Health-Related Research with*  
795 *Human*. 2011
- 796 World Medical Association (WMA) *Declaration of Helsinki – ethical principles for medical*  
797 *research involving human subjects*. 2013
- 798 World Medical Association (WMA) *Declaration of Taipei – ethical considerations regarding*  
799 *health databases and biobanks*. 2016
- 800 Other international laws such as EU regulations and directives
- 801 National laws
- 802 - Human rights
  - 803 - Patients' rights
  - 804 - Labor law (protection of the researchers as workers/employees)
  - 805 - Contract law
  - 806 - Liability law
  - 807 - Data protection law
  - 808 - Intellectual property law (authorship, patent ...)
  - 809 - Public health law
  - 810 - Therapeutic products law (medicinal products, medical devices, human cells, tissues and  
811 organs ...)
  - 812 - Biological safety, fight against epidemics
  - 813 - Education and research law
  - 814 - Scientific integrity (conflict of interest, scientific misconduct ...)
  - 815 - Anti-bribery law
  - 816 - Human research law
  - 817 - Biobanking law

818

## 819 Chapter 3: Scientific standards

### 820 Key words

821 *Expertise – Feasibility – Methodology – Scientific review – Study conduct – Study design – Rigor*  
822 *– Resources*

### 823 Background and Principles

824 The primary goals of health-related research are to understand human health and well-being, the  
825 causes, development and effects of diseases, and to identify or improve preventive, diagnostic  
826 and therapeutic interventions to maintain or restore health and improve quality of life. There are  
827 many useful approaches to health-related research, including clinical trials, observational studies,  
828 natural history studies, epidemiological studies, social science studies, and research using  
829 existing human biological material and data. Not necessarily depending on the approach, research  
830 involving human participants can be based on quantitative methods, qualitative ones or a mix of  
831 both. For all approaches, and regardless of the envisioned risks to the research participants,  
832 scientific rationale and methodological rigor are considered *sine qua non* ethical and scientific  
833 requirements. Attention to scientific quality, rigor and feasibility in the research objectives, design  
834 and methods is essential in order to assure the usefulness and quality of the data, avoid waste,  
835 and justify asking humans to participate while protecting their rights, safety, and well-being.

836 Studies also show that research produces blind knowledge by not including sex and gender  
837 differences in the design and not reporting sex or gender of participants in their results. This  
838 reduces reproducibility, resulting in a waste of resources, being a missed opportunity for  
839 innovation, causing harm and contributing to health inequity<sup>19</sup>. It is the responsibility of research  
840 institutions to ensure that researchers consider and account for sex and gender throughout the  
841 entire research process, including the conceptualization and design of research and the  
842 publication of results. The inclusion of sex and gender is not solely a matter of including men and  
843 women in trials, but rather it necessitates the collection and reporting of data that is disaggregated  
844 by sex, as well as meaningful sex- and gender-based analyses. In fact, a growing number of  
845 medicals journals and funding agencies are requesting today a gender-sensitive approach and/or  
846 gender equality plan.

847 In order to avoid as much as possible research waste, it is important to improve health related  
848 research workflow. The term “research waste” can be defined as research outcomes that cannot  
849 be used or with no societal benefits. That waste could be potentially avoided if the development  
850 of health-related research preceded by a systematic assessment of the existing evidence. In  
851 addition, the institution should encourage their researchers to perform health related research  
852 focused more on producing replicable results with social value instead of their own visibility  
853 through an H-index or on citations indexes<sup>20</sup>.

854 Much of the responsibility for scientific quality and integrity lies with the researchers. Yet,  
855 institutions that host research are responsible for making sure their researchers and research  
856 teams have the appropriate guidance, training, and support to conduct quality research and that  
857 there is sufficient review and oversight of the science and the research plans. To fulfill these

---

<sup>19</sup> Building back better: towards a gender-responsive international instrument for pandemic prevention, preparedness, and response, Consensus Statement. 2020. Available at: <https://www.gendro.org/consensus-statement>

<sup>20</sup> Chalmers I, Bracken M, Djulbegovic B, et al. *How to increase value and reduce waste when research priorities are set*. Lancet 2014; 383: 156–65.

obligations, institutions should ensure the quality, integrity, and rigor of the science and the scientific standards employed in their research. Research that is not scientifically sound and that cannot achieve its stated objectives is not considered ethical<sup>21</sup>.

## **Points to consider and how to address them**

### ***9. Awareness and coordination of proposed and ongoing research***

Quality research requires knowledge and skills, planning, coordination, caring and resources. Institutional attention to the significance of the research, the details of research design and conduct, and the feasibility of successfully completing the research are essential to protect participants and to generate useful and reliable knowledge, as well as compliance with regulations and efficient use of institutional and research resources.

Specific attention should be given to:

- Identifying applicable policies and guidelines for researchers or, when need be, establishing policies and adopting guidelines for them to understand requirements for protecting human participants, sharing of data, the mission and research scope of the institution, available support resources, and procedures for review and approval of the research proposals;
- Assuring compliance with applicable laws, regulations and institutional policies on human research and protection of personal information;
- Designating responsible individual(s) or, when need be, establishing a central office to assure awareness of research being conducted in the institution and that these studies are performed with high quality standard and aligned with institutional policies;
- Ensuring that institutional policies are inclusive and pay attention to removing biases in recruitment, and promotions and are gender sensitive;
- Ensuring that all involved services and committees within the institution are gender balanced and representative of the populations in which research is conducted;
- Ensuring that researchers are duly informed of the mission and research scope of the institution, the support resources available, and the procedures for review and approval of the research proposals;
- For institutions that are primarily intended for the provision of services define their research goals and approaches considering their legal and social mandate towards the served population and capability to assure compliance with quality standards of health research with the existing infrastructure and human resources;
- Depending on the intensity of research activities, developing and implementing standard operating procedures (SOPs) for interactions between investigators and the institution's research coordinating individuals or entities. The SOP should specify requirements for researchers including research staff during the planning and review of their research proposals, and then during the implementation and conduct of the approved studies;
- Assuring that the research plan is feasible and that the institution and the researchers have the necessary resources to fulfill their obligations derived from the implementation of the study, for example the retention of source documents and regulatory files for eventual inspections and/or need of re-contacting the participants after the closing of the study;
- Assuring that the data collection is well standardized in the institution and follow the ALCOA+ principles as detailed in Chapter 4: Collection, storage, and use of data and/or biological materials in health-related research;

<sup>21</sup> Council for International Organizations of Medical Sciences (CIOMS) *International ethical guidelines for health-related research involving humans*. 2016.

- Evaluating and mitigating the potential impact of diverting institutional human or material resources from healthcare activities towards research activities.

## ***10. Scientific value and appropriate research plan***

The goal of health-related research is to generate or contribute to generalizable knowledge about health and illness. This applies to both quantitative, qualitative and mixed methods research. An appropriate and rigorous design and careful conduct of research helps protect participant safety and the generation of reliable evidence.

A rigorous research proposal requires knowledge of particular areas of science and related research, reasons for the specific approach to answering the research question(s) and attention to whether the approach is feasible. A written research proposal or protocol should describe the study's justification, objective(s), design, methodology, statistical considerations and organization, qualifications of the research team, and other information to ensure the safety of participants and the quality and the integrity of the data collected.

Specific attention should be given to:

- Assuring clear and concise written research proposals or protocols that describe the study's justification, objective(s), design, outcomes, methodology, statistical considerations and organization, and other information;
- Considering adoption of a standard template for writing research protocols, based on existing country-specific or study topic-specific templates. Although the component parts of a given research proposal may differ for a variety of reasons, every research proposal should clearly state what the research question is, why it is important, how it improves upon what is already known, and how the design, methods, and procedures will be used to answer the question and determine the primary outcome (s);
- Even though ICH-GCP recommendation are intended to conduct interventional trials with drugs, compliance with ICH-GCP for all health-related research could be considered, when applicable, to ensure public assurance that the rights, safety and well-being of participants are protected;
- Assuring that the study design is consistent with accepted scientific principles, appropriate for answering the research question, and ethically acceptable. There should also be a feasible and clear plan for how data will be collected, analyzed, and reported in a scientifically appropriate manner;
- Assuring that the research protocols are attentive to sex and gender and inclusive of race, ethnicity, age, and other relevant considerations;
- Assuring that sex and gender considerations are taken into account during data collection, and analysis, that sample sizes allow for disaggregated data analysis based on sex and gender considerations and other relevant variables, or providing justification when they do not;
- Ensuring that the research is feasible and that the institution has the necessary resources and infrastructures to successfully complete the proposed research in order to avoid as much as possible research waste;
- Considering implementing Sager guidelines "sex and gender equity" if relevant for the research;
- Considering including participants or their representative (Patient and Public Involvement and Engagement, PPiE) and/or health care users in the process of the study design in order to avoid mismatch between what researchers want to do and what patients and local communities need and then improve social value of the study.

## 11. Scientific rigor—review and training

Planning and conduct of quality health related research require thorough and up-to-date knowledge of the study-specific topic, and / but also expertise in matters of scientific methodology, statistics, bioethics or research ethics, quality management, and legal and regulatory issues applicable to human research, patients' rights, and protection of personal information.

Institutions should have and support mechanisms for reviewing, evaluating, and providing oversight of health-related research. Such mechanisms are important to ensure scientific quality, reduce possible biases and waste, fulfill ethical standards, comply with regulations and laws, protect participants and other stakeholders, and maintain public trust. Some national laws allow for exceptions, but ethical guidelines and regulations require review by a research ethics committee (REC) before a health-related study begins. In addition, assessment of the scientific quality of the proposed research is necessary as "Bad science is Bad Ethics", and wastes resources.

Special attention should be given to:

- Assuring appropriate review of the science and scientific rigor of a proposed research design and plan. Scientific review should be provided by the competent REC/IRB or the appropriately constituted one. Alternatively, independent scientific review by a scientific review committee or designated individual(s), a peer review group, or some other mechanism is recommended, and should include individuals who have the expertise to evaluate the scientific questions and the methods proposed;
- Assuring that investigators and research team members have the proper skills and knowledge to conduct the proposed research. This may include knowledge and skills in the scientific and professional area as well as in appropriate and rigorous research methodologies;
- Considering referring to or providing initial and ongoing training on ethical standards, good practice and local and international regulations applicable to human research, and on scientific methodology, biostatistics, and scientific writing;
- Providing resources, whenever possible, such as methodologists, statisticians, research coordinators, and others who are experienced with the kinds of research being conducted in the institution and can support the investigators and research teams, or be part of the research team;
- Establishing a culture committed to the responsible conduct of science (see scientific integrity);
- Establishing a mechanism to monitor data and participant well-being throughout a research study (Chapter 9: Institutional Research Oversight).

**Table 4: Summary checklist for research institutions to assure scientific standards**

Infrastructure	Expertise & Training
<ul style="list-style-type: none"> <li>• Coordinating designated institutional research official(s) or establishing a research office</li> <li>• Institutional policy and SOPs for researchers and other staff involved in research (support) activities</li> </ul>	<ul style="list-style-type: none"> <li>• Access to expertise in methodology, research design, statistics, etc.</li> <li>• Training for researchers and research teams, and other key-staff involved in research (support) activities</li> </ul>
Tools	Review & Monitoring
<ul style="list-style-type: none"> <li>• Standard templates for written research proposals/protocols</li> </ul>	<ul style="list-style-type: none"> <li>• Process for scientific and ethics review of the rigor in the design and conduct of research</li> <li>• Plans for monitoring data</li> </ul>



## References

- Glasziou, P. & Chalmers, I. Research waste is still a scandal. *BMJ* 363, k4645 (2018).
- Chalmers I et al. *Lancet series on Research waste*; 383 (2014)
- AHRQ Essentials of a Research Plan. Available at <https://www.ahrq.gov/funding/process/grant-app-basics/esstplan.html>
- Department of Health and Human Services. Clinical trials e-protocol/template tool. Available at <https://www.hhs.gov/guidance/document/clinical-trials-e-protocol-templatetool-0>
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) *Guideline for Good Clinical Practice E6(R2) (ICH GCP)*. 2016
- Good Clinical Practice Network, Essential documents for the conduct of a clinical trial: ICH E6 (R2) Good clinical practice. Available at <https://ichgcp.net/8-essential-documents-for-the-conduct-of-a-clinical-trial>
- National Institutes of Health U.S. Protocol templates for Clinical Trials. Available at <https://grants.nih.gov/policy/clinical-trials/protocol-template.htm>
- Council for International Organizations of Medical Sciences (CIOMS) *International ethical guidelines for health-related research involving humans*. 2016
- Council for International Organizations of Medical Sciences (CIOMS) Working Group report: *Clinical research in resource-limited settings*. 2021
- World Medical Association (WMA) *Declaration of Helsinki – ethical principles for medical research involving human subjects*. 2013
- World Medical Association (WMA) *Declaration of Taipei – ethical considerations regarding health databases and biobanks*. 2016
- ALCOA + principles: Rattan AK. *Data Integrity: History, Issues, and remediation of Issues*. *PDA J Pharm Sci Technol*.72(2): 105-116, 2018.
- Building back better: towards a gender-responsive international instrument for pandemic prevention, preparedness, and response, Consensus Statement. 2020. Available at: <https://www.gendro.org/consensus-statement>
- European Association of Science Editors (EASE), Sex and Gender Equity in Research (SAGER) Guidelines. 2022. Available at: <https://ease.org.uk/wp-content/uploads/2023/01/EASE-SAGER-Checklist-2022.pdf.pagespeed.ce.Ni8gG8fm0D.pdf>
- Heidari, S et al, *Sex and gender equity in research: rationale for SAGER guidelines and recommended use*. *Research integrity and Peer Review*.1:2, (2016).
- Canadian Institutes of Health Research. *How to integrate sex and gender into research*. Available at: <https://cihr-irsc.gc.ca/e/50836.html>

## 1022 **Chapter 4: Collection, storage, and use of data and/or biological** 1023 **materials in health-related research**

### 1024 **Key word**

1025 *Biological materials – Biobank – Data – Databank - Participants' rights – Good custodianship –*  
1026 *Data protection – Data integrity and validation – Database – Informed consent – Source data*

### 1027 **Background and Principles**

1028 Collections of data and biological materials are important tools for health-related research which  
1029 contributes to a better understanding of diseases, health, health behaviors and the relationships  
1030 between the various factors that influence them. This guideline covers all collections of data and/or  
1031 biological materials, including those where the data and material are not stored but directly used  
1032 for a specific research project, as well as biobanks and databanks that involve secondary uses.  
1033 Of note, the term “use” of data and biological materials covers collection, analysis, storage,  
1034 archiving, sharing, exporting, reporting and destruction.

1035 As stated in 2016 CIOMS International ethical guidelines (Guideline 11)<sup>22</sup>: “When data and  
1036 biological materials are collected and stored, institutions must have a governance system to obtain  
1037 authorization for use and future use of these data and biological materials in research.  
1038 Researchers must not adversely affect the rights and welfare of individuals from whom the data  
1039 and materials were collected”.

1040 As a general rule, proper governance and good custodianship should protect the rights and  
1041 interests of individuals and promote quality research including data integrity. The governance  
1042 mechanisms should be comprehensive and correspond to the research institution's scope and  
1043 intensity of research activities. The governance measures enable promises to be kept to  
1044 participants, researchers, authorities, and other stakeholders in health-related research and foster  
1045 trustworthiness. Any activity, operation or procedure carried out or established during the life cycle  
1046 of collection and use should follow the principles of transparency, accountability, and inclusion of  
1047 interested persons in compliance with country's applicable national and international ethical and  
1048 professional standards and legal requirements.

1049 Institutions collect data and/or biological materials for different purposes including routine  
1050 diagnostic and clinical activities and research, but data collection is a more widespread practice  
1051 than biological material collection. Institutions must respect data protection principles and ensure  
1052 data integrity, quality, privacy and security.

1053 Data handling in the context of health-related research raises two major concerns. First, a key  
1054 component to conduct research is that the institution should provide adequate support/tools to  
1055 record source data. Indeed, the original medical records or patients' files (and/or certified copies  
1056 of original records) are the first place where some or all data relevant for a study are recorded,  
1057 representing the source documents/data of the research study (for instance according to ICH-  
1058 GCP 1.51 & 1.52 for clinical research). Secondly, the data flow in health-related research, meaning  
1059 the transcription of the source data into a study database and then their analyses should be well  
1060 planned, in compliance with applicable quality and regulatory standards, and ensure data integrity,  
1061 quality, privacy and security. High quality of data (source data as well as study data<sup>23</sup>, data

---

<sup>22</sup> Council for International Organizations of Medical Sciences (CIOMS). *International ethical guidelines for health related research involving humans*. 2016

<sup>23</sup> Study data is referring to clinical research data, internal clinical and/or research databank and biobank.

1062 collected in a databank and/or biobank) generated is a crucial condition for the validity of the  
1063 outcomes of research projects.

1064 In order to comply with the standards of good data handling, it is strongly recommended for the  
1065 institution to have some basic tools in place to conduct health-related research, such as a Clinical  
1066 Research Information System (CRIS).

1067

## 1068 **Points to consider and how to address them**

### 1069 ***12. Responsibilities towards the participants***

1070 Participants who accept to provide data and biological materials for health-related research have  
1071 rights and interests that must be protected throughout the life cycle of a project or a collection and  
1072 (re)use. The starting point is broad informed consent and confidentiality measures. These  
1073 mechanisms alone are not sufficient to protect the rights of participants; other transparent  
1074 measures and procedures must also be put in place. The participation of individuals depends on  
1075 their trust in the institution, which is why it is also important to include participants in the  
1076 development and execution of governance procedures whenever possible (see 2016 WMA  
1077 Declaration of Taipei, paragraph 20). The status of the broad informed consent (positive, negative  
1078 and withdrawal) and the terms of the agreement should be checked on an ongoing basis during  
1079 the collection of data and materials and during use or further use.

1080 Special attention should be given to:

- 1081 - Providing a template for the information and consent form. The informed consent could be  
1082 specific for a known project or broad informed if a further use is planned. Templates for  
1083 both forms should be available. Different information and consent forms should be  
1084 available for legally competent or incompetent adults and for children. Broad informed  
1085 consent may be a good solution for biobanks and databanks aiming for a data and  
1086 biological materials storage for further use. For further requirements on informed consent:  
1087 2016 WMA Declaration of Taipei, paragraphs 11-16, 2016 CIOMS International ethical  
1088 guidelines, Commentaries on guidelines 11 and 12<sup>24</sup>;
- 1089 - Ensuring a procedure for withdrawal of consent (how to contact, whom, where) and its  
1090 consequences is in place. The way of handling and/or destruction of data and biological  
1091 materials after withdrawal of consent should be specified;
- 1092 - Ensuring the follow-up of the consent decision (positive, negative and withdrawal) over the  
1093 time in order to make sure that the collected data and biological materials will not be used  
1094 for research purposes if participants refused or decided to withdraw their consent.
- 1095 - Ensuring a general procedure for re-contacting the participants, if needed;
- 1096 - Ensuring that the researchers are mindful of and pay special attention to including gender  
1097 diverse populations as well as including minority and other vulnerable populations in  
1098 various aspects of the research project;
- 1099 - Ensuring the confidentiality of the participants' data and biological material. For the data,  
1100 see point 5 "Data lifecycle". The coding of the samples should be the rule. Only a limited  
1101 number of qualified personnel should be able to link the code to the name of the source  
1102 person (i.e., have access to the key). The roles and responsibilities of team members, their  
1103 privileges and access rights should be defined and documented. For further requirements

---

<sup>24</sup> Council for International Organizations of Medical Sciences (CIOMS). *International ethical guidelines for health-related research involving humans*. 2016



- 1104 on confidentiality: 2016 WMA Declaration of Taipei, paragraph 10 and 21, 2016 CIOMS  
 1105 International ethical guidelines, Commentaries on guidelines 11 and 12<sup>25</sup>;
- 1106 - Ensuring that a procedure is in place to inform research participants and the general public  
 1107 about the ongoing research and research outcomes. This communication could be done  
 1108 through the general communication channels (such as the public website of the institution)  
 1109 and/or be included in the annual report available to the public;
  - 1110 - Assuring that a procedure on return of results and disclosure of (un)solicited/incidental  
 1111 findings is in place. Particular attention should be paid to results that have an influence on  
 1112 the health of the participants. The procedure should explain which findings will be  
 1113 communicated to the participants, how and by whom. The participants however may refuse  
 1114 to be informed of these results. For further requirements on return of results and disclosure  
 1115 of (un)solicited/incidental findings: 2016 CIOMS International ethical guidelines,  
 1116 Commentaries on guidelines 11 and 12<sup>26</sup>.

1117

### 1118 ***13. Access and transfer of data and biological materials***

1119 The use of stored data and biological materials implies first that researchers should have access  
 1120 to them. Rules of access and transfer, meaning who can request data and biological materials  
 1121 and how, should be put in place, in the respect of the limits of the informed consent and the  
 1122 principle of fairness as set out in the Global code of conduct for research in resource-poor settings,  
 1123 2018 (articles 1 to 7).

1124 Special attention should be given to:

- 1125 - Ensuring that the rules for transfer of data and/or biological materials are clarified. A legal  
 1126 agreement (such as Material Transfer Agreement (MTA) and/or Data Transfer Agreement  
 1127 (DTA)) should be used for the transfer of data and biological materials for research. Such  
 1128 agreement may also be included in the research protocol. This allows research institutions  
 1129 and researchers to protect the rights of the participants and to keep promises made  
 1130 through informed consent. If needed, templates of these documents should be made  
 1131 available to researchers. Research institutions should provide guidelines and/or designate  
 1132 dedicated experts to support researchers in adapting those templates to the settings of  
 1133 their research;
- 1134 - Providing guidelines on the rules for sharing collected data and/or biological materials with  
 1135 different types of users – such as researchers from the same institution or other institutions,  
 1136 or those coming from the academic sector, the commercial industry or governmental  
 1137 bodies;
- 1138 - Ensuring a procedure for handling requests for access to stored data and/or biological  
 1139 materials. If needed, a resource management committee could be set up to manage these  
 1140 requests. This committee could assess the scientific relevance of projects before sharing  
 1141 resources and check that projects have the authorization of the relevant REC. This  
 1142 committee could include members representing different groups such as the management  
 1143 of the institution (e.g., departmental or institutional level), researchers, healthcare  
 1144 professionals and persons representing the participants and communities contributing to  
 1145 the biobank or databank. If data and biological materials come from participants in multiple  
 1146 countries, representatives from these countries could also be included in the committee.


<sup>25</sup> Council for International Organizations of Medical Sciences (CIOMS). *International ethical guidelines for health-related research involving humans*. 2016

<sup>26</sup> Council for International Organizations of Medical Sciences (CIOMS). *International ethical guidelines for health-related research involving humans*. 2016

## 14. Biobank & Databank

The minimum requirements for setting up a biobank and a databank include the designation of persons responsible for its management, the preparation of documentation outlining its structure and activities, and the availability of resources necessary to achieve its purpose. Resources correspond to funding, qualified staff, infrastructure, a governance framework including PPI, and equipment, all of which must be planned for the long term. The institution has the responsibility to support researchers in their efforts to formalize their activities and assist with resource allocation or ensure that researchers have sufficient resources. A biobank and databank can only be qualified as an organized research setup if these minimal requirements are met, and a proper governance is in place.

**Figure 2: Biobank & Databank**



Special attention should be given to:

- Ensuring that the researchers have access to the guidelines and best practices available in the field (such as those listed in the references to these guidelines). Knowledge of these standards can be the first step in formalizing the types of biobanks or databanks (i.e., including biobank accreditation: ISO or other labels);
- Providing or identifying a template of document that describes the biobank or databank and its procedures, structures, and rules (a Regulation) in accordance with the applicable rules (see 2016 WMA Declaration of Taipei, paragraph 21 and 2016 CIOMS International ethical guidelines, Commentaries on guidelines 11 and 12<sup>27</sup>). The regulation should include the description of the biobank and/or databank and present the governance mechanisms. Guidelines could be made available to support researchers in adapting the template to the settings of their biobanks or databanks. The institution should consider having internal dedicated experts for advice and support to ensure that the information described in the regulation correspond to the real practice, that the structures are in place and that the rules and procedures correspond to daily management;
- Ensuring that the person(s) responsible of a biobank or databank is (are) designated with his/her (their) clear roles and responsibilities;
- Offering opportunities for participants and their communities or their representatives (PPIE) to be involved in the structures of the biobank or databank and/or in the

<sup>27</sup> Council for International Organizations of Medical Sciences (CIOMS). *International ethical guidelines for health related research involving humans*. 2016

creation/revision of the governance documents including but not limited to informed consent forms;

- Ensuring the availability of financial, personal, and material resources necessary to achieve the purposes. The first step is to define the objectives of the biobank or databank and identify the resources needed to achieve them. Then it is necessary to identify the resources currently available to the institution or directly to researchers and to find a balance between the available resources and the planned objectives. Resources considered should include financial support (i.e. a clear and transparent financial concept), qualified staff (i.e. enough persons with appropriate qualifications and training) and infrastructure/equipment (i.e. including a procedure for the acquisition and maintenance of the equipment and space);
- Ensuring a procedure in case of the end of activities or change of ownership.

### ***15. Operational requirements for the collection, storage and use of data and biological materials***

The operational measures must ensure the quality, security, integrity and privacy of the data and biological materials throughout the collection, storage, and use. For this purpose, a system for traceability should be setup and a basic quality management system (basic quality documents) should be available to the researchers. Traceability is also important to enable participants to exercise some of their rights (e.g. withdrawal of consent and its consequences). For specific requirement regarding data, see “Data lifecycle”.

Special attention should be given to:

- Ensuring that the collection of source data and study data (electronic system and/or paper based) follow the ALCOA+ principles, namely: data should be atttributable, legible, contemporaneous, original, accurate, complete, consistent, enduring and available;
- Ensuring that standard operating procedures (SOPs) are available and operable, describing how technical and/or administrative activities are conducted, including detailed process addressing what, who, where and how these are to be performed.


Specifically for biobanks, special attention should be given to:

- Ensuring that the biobank facilities and equipment are aligned with the overall missions / objectives of the biobank. In particular, the biobank room must meet the requirements to provide safe space for the staff and biological materials stored, with controlled access;
- Assuring that guidelines regarding biosafety measures related to work in laboratory are in place;
- Ensuring that appropriate records and/or laboratory information management systems (i.e. LIMS or others) are in place to track the movement of biological materials (i.e. from collection to storage, retrieval and return);
- Assuring to have a procedure regarding medical waste that can be used for disposal and destruction of biological materials.

### ***16. Data lifecycle***

Data management or data lifecycle is the process of collection, cleaning, and management of data in compliance with regulatory standards. The primary objective of the data management process is to ensure data accuracy, integrity, quality, privacy, and security. The tools available for researchers in the institution should comply with a data life cycle in order to improve the quality of the primary data collection but also to facilitate the conduct and support the data quality control of the study.

1225 **Figure 3: Data lifecycle**



1226

1227

1228 Special attention should be given to:

- 1229 - Assuring to have in place a template of document (such as a Data Management Plan, DMP) that describes the procedures to be followed in the preparation and documentation of the collection of the data (e.g. electronic database). This document should describe all the steps to handle data from collection to archiving as illustrated by **Figure 3: Data lifecycle**;
- 1230 - Assuring that the database system available in the institution used to support a study, clinical and research databank and biobank is designed to prevent errors in data collection, modification, maintenance, archiving, retrieval or transmission. If electronic database cannot be used in the institution for any reasons, the data flow must be well documented;
- 1231 - Assuring simplified guidelines are in place and/or dedicated experts are available to support the researchers in the different process of database design and development and data validation;
- 1232 - Assuring that study data can be stored in such a way that backup copies can be easily and frequently made. In principle, paper documents should be scanned, stored, and archived electronically, they will be either included with the backup with other study files or stand-alone;
- 1233 - Assuring the availability of a physically secure room with controlled access available to the researchers to archive all the study paper documents and electronic dedicated spaces on secure servers to archive all electronic the study data;
- 1234 - Database servers should be physically secured with controlled access. Direct access to database servers should be restricted to individuals who are responsible for system monitoring and data backup;
- 1235 - Assuring that your institution has a process in place to perform quality control and cleaning of the data either electronically or manually (see Chapter 9: Institutional Research Oversight);
- 1236 - Assuring that the institution has a process in place to make the research databank openly available for reuse by the community after the data publication process, in accordance with FAIR Data principles/Open access, whenever applicable.

1257

1258 **References**

- 1259 World Medical Association (WMA) *Declaration of Helsinki – ethical principles for medical*  
1260 *research involving human subjects*. 2013
- 1261 World Medical Association (WMA) *Declaration of Taipei – ethical considerations regarding*  
1262 *health databases and biobanks*. 2016
- 1263 Council for International Organizations of Medical Sciences (CIOMS) *International ethical*  
1264 *guidelines for health-related research involving humans*. 2016
- 1265 Council for International Organizations of Medical Sciences (CIOMS) Working Group report:  
1266 *Clinical research in resource-limited settings*. 2021
- 1267 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for  
1268 Human Use (ICH) *Guideline for Good Clinical Practice E6(R2) (ICH GCP)*. 2016
- 1269 ICH Good Manufacturing Practice (GMP), Good Clinical Laboratory Practice (GCLP).
- 1270 International Organization for Standardization (ISO). Biotechnology -- Biobanking -- General  
1271 requirements for biobanking (ISO standard n° 20387:2018).
- 1272 International Society for Biological and Environmental Repositories (ISBER), Best Practices:  
1273 Recommendations for Repositories, Fourth Edition 2018.
- 1274 International Agency for research on Cancer (IARC), Common minimum technical standards and  
1275 protocols for biobanks dedicated to cancer research, 2017.
- 1276 Recommendation CM/Rec(2016)6 of the Committee of Ministers to member States on research  
1277 on biological materials of human origin.
- 1278 ALCOA + principles: Rattan AK. Data Integrity: History, Issues, and remediation of Issues. PDA J  
1279 Pharm Sci Technol.72(2): 105-116, 2018.
- 1280 Clinical Trials Information system (CTIS) – technical requirement for optimal use (EMA), 2022.  
1281 [CTIS technical requirements for optimal use 2022.02.22 \(europa.eu\)](https://ec.europa.eu/health/ctis/technical_requirements_for_optimal_use_2022_02_22_en)
- 1282 U.S. Code of Federal Regulations, Title 21, Part 11 (21.CFR.11).
- 1283 Data Management Plan <https://www.fda.gov/media/131750/download>
- 1284 Wilkinson M.D *et al.* Comment: The FAIR Guiding Principles for scientific data management and  
1285 stewardship. Scientific data. 3:160018, 2016.
- 1286



## 1287 **Chapter 5: Financial Management and Budgeting**

### 1288 **Key words**

1289 *Alternative institutional resource – Anti-bribery – Budget – Budget structure – Cashflow – Conflicts*  
 1290 *of interest – Cost recovery – Direct cost – Fair market value – Financial audit – Financial statement*  
 1291 *– Fixed cost – Indirect cost – Line item cost – Payment schedule – Per volunteer cost – Recurring*  
 1292 *institutional resource – Transparency*

### 1293 **Background and Principles**

1294 Comparing with common areas such as research ethics, research participants protection,  
 1295 regulatory and legal compliance, management, data disclosure and publication, discussions on  
 1296 budgeting and financial management are relatively limited in the domain of health-related  
 1297 research. This may be attributable to the wide diversity of financial objectives, funding sources,  
 1298 funding structures and financial management policies among research institutions and research  
 1299 teams involved in different types of health-related research, leading to the difficulty in  
 1300 recommending generalizable budget structure and financial management policies applicable to all  
 1301 research institutions.

1302 Good quality does not come without cost, but poor quality may induce even higher cost to research  
 1303 institutions. Inappropriate or inefficient financial planning and management could jeopardize the  
 1304 management of research institutions and their research projects. It may hamper the institutions'  
 1305 success and sustainability and their research projects' quality, and even compromise their primary  
 1306 mission as well as the interest of research participants and the public.

1307 Whilst recognizing the diversity in financial objectives, policies and practice among research  
 1308 institutions, this chapter outlines four key areas in financial management for consideration by  
 1309 research institutions, including:

- 1310 • institutional resources planning;
- 1311 • project budgeting;
- 1312 • financial administration; and
- 1313 • financial compliance.

### 1314 **Points to consider and how to address them**

#### 1315 ***17. Institutional Resources Planning***

1316 Setting up good governance practice for a research institution is a substantial and long-term  
 1317 commitment, which requires:

- 1318 • investment on initial setup;
- 1319 • allocation of resources for the institution's continuous operation; and
- 1320 • availability of resources for individual research projects.

1321 Manpower and facilities/equipment are the major resources required by any research institution,  
 1322 but viable institutions need more than these. Depending on the targeted scopes and volume of  
 1323 research, research institutions may have their specific cost structures and therefore different sets  
 1324 of cost items. A list of common cost types and cost items are highlighted in **Table 5: Common**  
 1325 **cost types and cost items for research institutions** below for reference.

1326

1327 **Table 5:** Common cost types and cost items for research institutions

Cost Type Cost Category	Cost Item Examples		
	Initial Setup Costs	Recurring Costs	Project Costs
<b>Facilities &amp; Equipment</b>			
Spaces, fixtures & fittings	Renovation, furniture	Repairing & maintenance	Project-specific facilities
Equipment	Office equipment, research equipment	Repairing & maintenance	Project-specific equipment
<b>Staffing</b>			
Salaries & benefits		Management staff, research/technical staff, supporting staff	Project-based staff
Training & development		Training courses, conferences, meetings	Project-specific training & meetings
<b>Information Technology</b>			
Hardware	Servers, computers, handheld devices, accessories	Repairing & maintenance	Project-specific hardware
Software subscription	Software licence subscription	Software licence renewal	Project-specific software subscription & renewal
Application development	Tailored application development	Application maintenance, debugging & upgrading	Project-specific application development & maintenance
IT services		Data hosting, cloud services, information security services	Project-specific IT services
<b>Compliance &amp; Risk Management</b>			
Licences	Initial licence applications	Licence renewal	Project-specific licences/permissions
Accreditation	Initial accreditation applications	Participation in accreditation programmes	Project-specific accreditation application & maintenance
Business insurance		Medical malpractice, professional indemnity, public liability, property risk	Project-specific insurance
<b>Operating Expenses</b>			
Utilities		Electricity, gas, water	Project consumption
Consumables		Office consumables, research consumables	Project-specific consumables
Telecommunication, postage & courier		Phone/fax lines, international courier	Communication with collaborators & research participants

Cost Type Cost Category	Cost Item Examples		
	Initial Setup Costs	Recurring Costs	Project Costs
Travelling & accommodation		Local transportation, overseas trips	Attending project meetings
Communications & marketing		Marketing materials, marketing events, newsletters, websites, social media	Project promotion, research volunteer recruitment
Outsourced services		Housekeeping, warehouse	Project-specific services

Individual research projects should in general be funded by project-specific resources such as research grants and industry sponsorship. Researchers are responsible for soliciting the required grants/sponsorship by leveraging their research merits which address scientific, social and public health needs. Establishment and maintenance of a research institution's human, facility and system infrastructure, however, should be financed by a combination of **"recurring institutional resources"** and **"alternative institutional resources"** as outlined in **Table 6: Recurring and alternative resources available to research institutions** below.

**Table 6: Recurring and alternative resources available to research institutions**

Examples of Recurring Institutional Resources	Examples of Alternative Institutional Resources
<ul style="list-style-type: none"> <li>Research institution's regular funding</li> <li>Research institution's regular business incomes</li> <li>Indirect/overhead fees generated from research projects</li> </ul>	<ul style="list-style-type: none"> <li>Non-recurring government funding</li> <li>Charity funding</li> <li>Donations</li> <li>Special grants</li> <li>Research institution's reserve funds</li> </ul>

Initial step toward good governance practice of a research institution could be financed by one-off alternative resources, depending on the type and scale of establishment. Continuing maintenance and operation of a research institution should be funded by recurring resources to ensure long-term sustainability. Dedicated research institutions are regularly engaged in many research projects and may generate sufficient resources by charging indirect/overhead fees out of the budgets for their research projects. Non-dedicated research institutions, however, may not have a stable and sufficient number of research projects to achieve a sustainable level of income. Hence, commitment by institutional management to continuously allocate necessary resources from their recurring institutional budgets is necessary. This is important to note that commitment of recurring resources does not necessarily imply perpetual allocation of substantial budgets. A research institution with a small number of research projects may easily kick-start its research establishment by a small budget covering only basic costs (e.g. minimal staff and facility costs). If and when research activities start to rise, contributions from indirect/overhead fees will increase in parallel and gradually become the major financial resources for supporting the research institution's continuing operation.

### **18. Project Budgeting**

Most research institutions, in particular public institutions or charities, do not aim to earn profits out of their research projects. However, they should at least secure the principle of **"cost recovery"** to ensure sufficient resources are made available for proper performance of their projects in accordance with all ethical, legal and quality standards.



Different funding bodies may have different requirements on budget structures and presentation, and different research institutions may have different financial management policies. This section primarily gives a general guidance to research institutions and their researchers on preparing their research budget proposals from three key perspectives including:

- cost types and cost items;
- budget structure; and
- payment terms and schedules.

**Direct and Indirect Costs:** A project budget usually comprises “**direct costs**” and “**indirect costs**”. Direct costs are costs and expenses which are directly incurred from project activities, whilst indirect costs are costs that do not directly arise from a project but are apportioned from an institution’s general overhead costs and expenses such as office facility and administrative costs. The following table gives some examples of direct and indirect costs applicable to a research project:

**Table 7: Direct and indirect costs for research projects**

Project Cost Types		Examples of Project Cost Items
Direct Costs	Staff Costs of Research Personnel	<ul style="list-style-type: none"> <li>• Salaries of research staff specifically employed for research project</li> <li>• Apportioned manpower costs of existing research staff</li> </ul>
	Equipment and Supplies	<ul style="list-style-type: none"> <li>• Project-specific equipment</li> <li>• Project-specific software</li> <li>• Research evaluation tool licences</li> <li>• Project-specific consumables (e.g. laboratory, drugs etc.)</li> </ul>
	Data Communication	<ul style="list-style-type: none"> <li>• Wide area network (WAN) setup specifically to meet the requirements of a research project</li> </ul>
Indirect Costs		<ul style="list-style-type: none"> <li>• Licence fee of general software</li> <li>• Maintenance fee of general equipment</li> <li>• Rental of research institution’s regular offices</li> <li>• Salaries of regular administrative staff</li> </ul>

Since it is not straight-forward to objectively apportion indirect costs to individual projects, research institutions usually apply a standard overhead charge as a percentage (e.g. usually in the range of 15 to 30%) of the direct costs for the convenience of budgeting and administration. A research institution should consider its funding structure and set a reasonable overhead charge rate which aligns with the principle of cost recovery and at the same time allows sufficient resources allocated to cover the direct project costs.

**Budget Structure:** A budget structure may be directed by funding bodies, but the principles of budget estimation remain valid. For instance, the budget structure requested by governmental funding bodies may adopt a modular concept, i.e. budget presented as a lump-sum for each area of activities (e.g. protocol development, statistical analysis). For commercial driven studies, however, commercial sponsors normally request detailed presentation of itemized costs in form of a budget spreadsheet under three major categories, including:

- fixed costs (i.e. basic costs that are incurred for setting up a project irrespective of the actual number of research participants recruited in the project or research activities performed);
- per participant costs (i.e. costs that are incurred from the participation of each research participant); and

- 1390 • line item costs (i.e. costs that are incurred only if a certain activity is performed).

1391 **Table 8: Budget structural categories and corresponding cost items for research**  
1392 **projects**

Budget Structural Categories	Examples of Cost Items
Fixed Costs	<ul style="list-style-type: none"> <li>Professional indemnity and insurance, research ethics committee fee, participants recruitment, regulatory submission fee, pharmacy setup cost, laboratory tests setup cost, drug cost</li> </ul>
Per Participant Costs	<ul style="list-style-type: none"> <li>A summation of cost of performing study procedures per each study visit (per visit cost) during the entire study for each participant. Example of cost items for study procedure: conducting informed consent, checking eligibility criteria, performing physical examination, data collection, performing internal quality check, drug dispensing, subsidy to volunteer</li> </ul>
Line Item Costs	<ul style="list-style-type: none"> <li>Laboratory tests or imaging assessments that will only be performed if needed</li> </ul>

1393

1394 **Payment Terms and Schedules:** In addition to the total amount under a budget, “cashflow” is  
1395 also very important. Despite the variation of budget structures, research institutions should pay  
1396 attention to the payment terms and schedules to ensure that sufficient funding is received for  
1397 covering the expenses during different stages of a research project. For example, if the first  
1398 payment under a budget will only be received by the research institution upon recruitment of 100  
1399 volunteers, the institution and the researcher may not have resources to set up the project and  
1400 perform the works before recruitment completion and the project could end up a failure. Close  
1401 monitoring of project progress and regular processing of payments (e.g. quarterly) during the  
1402 project period are therefore highly recommended to maintain a healthy cashflow for supporting  
1403 the success of a research project.

## 1404 **19. Financial Administration**

1405 Researchers are experts in health and science but, in general, may not be so skillful in finance  
1406 and accounting. Nonetheless, proper administration of financial transactions and maintenance of  
1407 financial records, from commencement until completion of a research project, are essential for  
1408 assurance of financial compliance and facilitation of financial audits irrespective of the nature of  
1409 funding received. Research institutions therefore should assist researchers in managing financial  
1410 transactions, maintaining accounting records and preparing financial statements through:

- 1411 • providing routine consultancy services to researchers via its research administration office  
1412 or finance department;
- 1413 • organizing regular training workshops in relation to research financial administration and  
1414 compliance;
- 1415 • developing financial statement templates specific for health-related research for reference  
1416 by researchers; and
- 1417 • supporting internal/external financial audits.

1418 Institutions dedicated to research, and with a high and regular volume of research projects, may  
1419 also consider to establish a central research office to undertake the aforesaid financial  
1420 administrative duties in collaboration with their researchers.

1421

## 20. Financial Compliance

Financial compliance is crucial in health-related research projects, whether for those supported by public or private resources. In particular, research institutions should establish appropriate guidance and mechanism to avoid conflicts of interest and bribery/corruptive actions.

Without prejudice to other chapters discussing the importance of declaration of conflicts of interest, research institutions and researchers are strongly recommended to undertake the following measures to avoid any “perceived” or even “real” conflicts of interest from the perspective of financial management:

- Upholding Transparency of Research Budget: Budgets should be open for independent audits and inspections by internal quality departments and regulatory agencies;
- Proper Documentation: Budget table with detailed cost items and breakdown to assure there are no hidden cost items. If possible, more than two quotations should be collected from different vendors for items to be procured to avoid procurement bias.

Research institutions should, and should procure that their researchers, observe all applicable local and international laws and regulations in relation to anti-bribery and anti-corruption (e.g. US FCPA, UK Bribery Act<sup>28</sup>).

When a research project is supported by a third party, the research budget must be prepared based on the actual procedures and requirements defined in the study protocol without taking into account any other business relationships. It is also recommended that a research budget should be compiled according to the principle of “fair-market-value,” which could be demonstrated by documented market information and consistency across research projects. If an agreement is executed between a funding body and a research institution, it should specify that all the payments by the funding body under the agreement should be made only to the research institution but not directly to the researcher or any individual person to avoid any possibility or suspicion of bribery.

---

<sup>28</sup> *The Foreign Corrupt Practices Act of 1977 (FCPA)*, Pub. L. 95-213, 91 Stat. 1494 (1977), 15 U.S.C.

1447 **References**

- 1448 American Institutes for Research: AIR Code of Conduct. Arlington, VA, 2022.  
1449 <https://www.air.org/code-conduct>.
- 1450 Clinical Research Management and Compliance (2nd ed.) Hong Kong: Hospital Authority 2015.  
1451 [https://www.med.hku.hk/images/document/04research/institution/ha\\_handbook\\_on\\_Clinical\\_Research.pdf](https://www.med.hku.hk/images/document/04research/institution/ha_handbook_on_Clinical_Research.pdf)  
1452
- 1453 Cornell Research: Research Services <https://researchservices.cornell.edu/resources/direct-and-indirect-cost-examples>  
1454
- 1455 Estonian Code of Conduct for Research Integrity. Tartu, 2017. <https://www.eetika.ee/en/ethics-estonia/estonian-code-conduct-research-integrity>.  
1456
- 1457 Feinberg School of Medicine: Research Administration Services. Melin M. Research Finance:  
1458 Constructing Budgets and Managing Projects (ppt). January 2012.
- 1459 German Research Foundation: Guidelines for Safeguarding Good Research Practice. Code of  
1460 Conduct. Bonn, 2019. Status: November 2021 / revised version 1.1. URL  
1461 [https://www.dfg.de/download/pdf/foerderung/rechtliche\\_rahmenbedingungen/gute\\_wissenschaftliche\\_praxis/kodex\\_gwp\\_en.pdf](https://www.dfg.de/download/pdf/foerderung/rechtliche_rahmenbedingungen/gute_wissenschaftliche_praxis/kodex_gwp_en.pdf).  
1462
- 1463 Kelly Willenberg Research Compliance Advocates. Willenberg K. Fair Market Value and Clinical  
1464 Trial Budgets (ppt).
- 1465 World Health Organization: Code of Conduct for Responsible Research. 2017. URL  
1466 <https://eneri.eu/wp-content/uploads/2018/10/code-of-conduct-responsible-research.pdf>  
1467

## 1468 Chapter 6: Collaboration

### 1469 Key words

1470 *Accountability – Collaboration agreement – Data protection – Data rights and ownership – Data*  
 1471 *sharing – Fair partnership – Intellectual property rights – Public disclosure – Research interest –*  
 1472 *Samples sharing – Transparency*

### 1473 Background and Principles

1474 Each research institution, like any other organizations, exists for a specific social purpose (see  
 1475 Chapter 1: Research Institution Management). With the rapid advancement in health sciences,  
 1476 increasing awareness of diversity (whether socio-economical, ethnic, cultural, gender or  
 1477 otherwise), and increasingly stringent ethical, regulatory and quality requirements worldwide,  
 1478 health-related research is becoming more challenging. Challenges can be even greater for those  
 1479 organizations that carry out research outside their core mandate (such as some NGOs and some  
 1480 international organizations). Research institutions may therefore encounter constraints that limit  
 1481 the extent of achievement of their research objectives on their own. Collaboration between  
 1482 research institutions and/or with other partners could be considered as opportunities to help  
 1483 overcome such constraints.

1484 Collaboration is the act of two or more parties working together within a mutually agreed scope to  
 1485 achieve certain goals that bring shared benefits/outcomes. A collaboration could be established  
 1486 for a particular project or event (e.g. a research project, a joint research seminar, etc.), or for a  
 1487 strategic purpose covering a certain scope or series of projects or activities (e.g. a research  
 1488 program consisting of a number of research projects around a certain discipline, a long-term  
 1489 research personnel development program involving exchange and placement of staff, etc.). A  
 1490 successful collaboration may, in addition to achieving the defined collaboration goals, also bring  
 1491 extended long-term benefits to the concerned institutions, the researchers and the research  
 1492 community at large, by:

- 1493 • supporting the achievement of the research institutions' organizational missions;
- 1494 • supporting the development of new research and research-supportive skills and
- 1495 capacities;
- 1496 • supporting the upgrade of the research institutions' infrastructure and skills;
- 1497 • creating and/or supporting long-lasting collaboration among the researchers;
- 1498 • encouraging and facilitating exchange of good research and governance practices;
- 1499 • developing a larger network of like-minded institutions;
- 1500 • contributing to the continuing improvement of the local, national and/or international
- 1501 research environments.

1502 In the domain of health-related research, collaborations are usually driven by researchers with  
 1503 common research interests. It would be very important that research institutions – in line with their  
 1504 research scopes and missions – offer necessary and appropriate supports to their researchers  
 1505 and exercise good governance over their collaborative projects and activities.

1506 Collaboration is not a purpose by itself, but it is a useful way of facilitating the achievement of the  
 1507 research purposes of research institutions and their researchers. To work out a meaningful and  
 1508 fair collaboration that create value for all collaborating parties, it is highly recommended that  
 1509 research institutions and researchers, prior to the start of the collaboration:

- 1510 • identify suitable collaborators;
- 1511 • formulate a collaboration plan and define the way of execution;
- 1512 • stipulate the agreed terms and conditions in a collaboration agreement (or equivalent).



1513 It is also highly recommended that research institutions continue to oversee the performance of  
 1514 collaborative activities throughout the entire period of collaboration (see Chapter 9: Institutional  
 1515 Research Oversight) and evaluate the immediate outcomes upon conclusion of the collaboration  
 1516 and, when applicable, the long-term outcomes at defined time after its formal conclusion.

## 1517 **Points to consider and how to address them**

### 1518 ***21. Identification of Suitable Collaborators***

1519 Identifying suitable, like-minded collaborators is the pre-requisite for a successful collaboration.  
 1520 Depending on the subject domain and context, a research institution may collaborate with entities  
 1521 such as:

- 1522 • other public/private health research institutions;
- 1523 • non-health research institutions (for instance, in the field of economics and other social  
 1524 sciences);
- 1525 • industry/commercial corporations;
- 1526 • professional associations;
- 1527 • governmental bodies;
- 1528 • international organizations;
- 1529 • non-governmental organizations or charity organizations;
- 1530 • patient associations;
- 1531 • specialized bodies (e.g. reference diagnostic laboratories);
- 1532 • funding bodies.

1533 Solid collaboration among collaborators is founded on three fundamental elements including:

- 1534 • common research interests;
- 1535 • shared values and common goals of collaboration;
- 1536 • complementary qualities/elements that justify the collaboration.

1537 No research institutions will ever be the same, but in order to work together it is important that  
 1538 they share certain common research interests, common values and common goals. Furthermore,  
 1539 it is desirable that collaborators carry complementary qualities/elements – whether in terms of  
 1540 expertise, capacity, financial resources, human resources, facilities, time, regulatory environment,  
 1541 access to research population, local culture or otherwise – that supplement the limitations of the  
 1542 other collaborators and/or enhance the synergistic outputs out of the collaboration.

1543 *For example*, university epidemiologists, university social scientists and elderly homes in a city  
 1544 may all be interested in exploring the pattern of spread of an infectious disease in the elderly  
 1545 population, and have the common goal of protecting the health of the elderly by preventing disease  
 1546 transmission within confined nursing facilities using an evidence-based approach. On these  
 1547 common grounds, they could jointly organize a collaborative research project on the subject matter  
 1548 utilizing their complementary strengths, under which the university, epidemiologists and social  
 1549 scientists offer their research personnel and research expertise, and the elderly homes offer their  
 1550 expertise in elderly care and provide access to their nursing facilities and potential research  
 1551 participants.

1552 In spite of the wide diversity of research institutions, it seems critical that special attention is paid  
 1553 to the principle of “**fair partnership**” which consists of three domains including:

- 1554 • **fairness of opportunity**: which refers to the fair opportunity to contribute to the  
 1555 collaboration (e.g. in terms of defining the collaborative scope, goals, methodologies,  
 1556 management mechanism, roles, financing and contractual arrangements, etc.);

- **fair process:** which refers to the fair management and operation of a collaboration (e.g. data use and ownership, transfer and future use of biological materials, centralized versus decentralized processes, etc.);
- **fair sharing of benefits/outcomes and costs/liabilities:** which refers to the fair sharing of collaborative benefits/outcomes corresponding to each party's inputs and contributions, both at research institution's and researcher's level (e.g. authorship policies, intellectual property rights, technology transfer, training opportunities, etc.); and the undertaking of costs/liabilities corresponding to each party's responsibilities and shared benefits/outcomes (e.g. insurance, indemnity, etc.).

## 22. Collaboration Plan and Concerted Execution

Each research institution may have different practices and follow different standards applicable to its own scope of activities. To ensure all collaborating parties will work towards the common goals and deliver the expected outputs under a collaboration, it is very important that they jointly formulate a collaboration plan and define the way of execution.

A collaboration plan generally consists of essential components including but not limited to:

- **the context of collaboration:** detailing the objectives, rationales, arrangements, deliverables and expected outcomes of collaboration (and in case of a collaborative research project, including the research protocol);
- **a duties allocation plan:** defining the delegated roles and responsibilities of each collaborating party;
- **a time plan:** defining the key milestones and estimated time schedule;
- **a financial plan:** setting out the budget, funding sources and cash flow (see Chapter 5: Financial Management and Budgeting);
- **a compliance, quality and risk management plan:** listing the ethics, regulatory and quality standards to be followed (see Chapter 2: Ethics, Law and Scientific Integrity), the measures to be applied to monitor compliance (see Chapter 9: Institutional Research Oversight), and the measures to be taken to prevent and control risks (see Chapter 1: Research Institution Management).

It is important to note that, even if the specific formulation of the plan will depend on the kind of research, these five recommendations are applicable across all research disciplines. *For instance*, the specific measures to be applied to monitor compliance will be different across clinical trials, epidemiological studies, pharmacoeconomic studies and behavioral studies, but monitoring compliance is equally important in all these studies.

Effective execution of a collaboration plan relies on the concerted efforts of all collaborating parties. It is therefore recommended that research institutions and researchers pay attention to:

- **governance:** by jointly establishing and authorizing a steering committee (or equivalent) governing the collaboration (with documented terms of reference and key-decisions made);
- **sharing of responsibilities:** by fairly allocating responsibilities among the collaborating parties, with special attention to avoid asymmetries of power;
- **delegation of project team:** by delegating their representatives (e.g. project managers, coordinators, data managers, field data collectors, etc.) to perform communication, management and operation of the collaboration;
- **communication and execution:** by defining the way of communication (e.g. by regular meetings, progress reports) and aligning the practical arrangements for exercising their duties (e.g. how data are collected, analyzed, interpreted, stored, accessed, transferred, published and disseminated, etc.).

### 23. Collaboration Agreements

To ensure that a collaboration is fully transparent to all the collaborating parties and for the avoidance of misunderstanding and dispute, it is highly recommended that the detailed terms and conditions of collaboration (in particular each party's rights, responsibilities and liabilities) are clearly stipulated in a collaboration agreement (or equivalent) among the collaborating research institutions. Such agreement terms and conditions are desirably written in such a way that reflects the core principles of:

- **fair partnership:** as outlined in point to consider 221 above;
- **ethical and legal conduct:** all the parties sharing the responsibility of complying with the applicable ethical and legal requirements in performing their responsibilities under the collaboration;
- **transparency and accountability:** public disclosure of collaborative activities and results being warranted and planned for any health-related research, irrespective of research disciplines and contexts.

In this connection, it is recommended to pay special attention to the contractual provisions relating but not limited to:

- applicable (national and international) ethical and legal standards;
- data and sample rights and ownership;
- intellectual property rights and ownership;
- publication and public disclosure of results;
- data protection;
- right of termination;
- liabilities, indemnity and insurance.

Last, it is very important that all legal professionals, researchers and management executives familiar with the context and operation of the collaboration are timely involved in developing the agreement to ensure that all legal, scientific and operational perspectives are well considered and the agreement is practically operable. The agreement will be entered in the capacity of the collaborating institutions and executed by their authorized representatives to ensure enforceability. The responsible researchers and/or key personnel may also be required to provide their written acknowledgement on the agreement to confirm their understanding and consent to the terms and conditions.

For the avoidance of doubt, the existence of a collaboration agreement does not replace the need for other specific contracts or agreements (e.g. material transfer agreements, data sharing agreement, etc.).

1639 **References**

- 1640 World Medical Association (WMA) *Declaration of Helsinki – ethical principles for medical*  
 1641 *research involving human subjects*. 2013
- 1642 World Medical Association (WMA) *Declaration of Taipei – ethical considerations regarding*  
 1643 *health databases and biobanks*. 2016
- 1644 Council for International Organizations of Medical Sciences (CIOMS) *International ethical*  
 1645 *guidelines for health-related research involving humans*. 2016
- 1646 Council for International Organizations of Medical Sciences (CIOMS) Working Group report:  
 1647 *Clinical research in resource-limited settings*. 2021
- 1648 *Global Code of Conduct for Research in Resource-Poor Settings*. 2018
- 1649 *The FAIR Guiding Principles for scientific data management and stewardship*. 2019
- 1650 European Federation of Academies of Sciences and Humanities (ALLEA). *The European Code of*  
 1651 *Conduct for Research Integrity*. 2017
- 1652 Council on Health Research for Development (COHRED) Research Fairness Initiative  
 1653 <https://rfi.cohred.org/>
- 1654 International Committee of Medical Journal Editors (ICMJE) *Defining the Role of Authors and*  
 1655 *Contributors*. Available at <https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>
- 1657 Committee on Publication Ethics (COPE). *Principles of Transparency and Best Practice in*  
 1658 *Scholarly Publishing*. 2022. Available at: <https://publicationethics.org/sites/default/files/principles-transparency-best-practice-scholarly-publishing.pdf>
- 1660

## Chapter 7: Communication

*Accountability – Community engagement – Communication – Ethics – Honesty - Integrity – Intranet – Media – Policy makers – Publication – Research dissemination – Social Media – Stakeholder engagement – Transparency – Website*

### **Background and Principles**

Each research institution has a specific mandate and social purpose. With the rapid advancement in health sciences, the availability of multiple ways of communicating within and outside the scientific community, and the increasing societal awareness of the need of accountability and transparency, both research institutions and individual researchers face increasing challenges in adequately communicating on the research undertakings and findings. Nonetheless, transparent communication is essential for ensuring internal and public accountability and thus for realizing the social and scientific value of health-related research.

It is recommended that a communication plan is articulated at various levels:

- Internally – Within the research organization or consortium (see also Chapter 1: Research Institution Management and Chapter 7: Communication).
- Externally – Toward peers within the scientific community;
- Externally – Toward institutions that oversee research (see also Chapter 2: Ethics, Law and Scientific Integrity);
- Externally – Toward the research community;
- Externally – Toward the mainstream and social media;
- Externally – Toward policy-makers in health systems.

A well-thought internal communication plan may ensure that everybody in the organization and in the research consortium have clear and easy access to policies, procedures, decisions made etc. In addition, it will contribute to creating a climate of transparency, mutual learning and trust, and to the continuing improvement of their research policies and practices.

In order to achieve effective internal communication, it is desirable that a research organization acts both at project level, i.e. by communicating on plans, policies and achievements about a specific research project, and at a broader institutional level, i.e. by communicating on scientific, ethics and legal policies and regulations that govern research and research supporting activities.

A well-thought external communication plan may in first place support organizational and individual compliance with research ethics and integrity principles. In addition, it will contribute to building a solid scientific reputation for the institution and for the individual researchers; and to the continuing improvement of the local, national and/or international research environments.

In order to achieve effective external communication, it is recommended that a research organization acts both at project level, and at institutional level. At project level, it is desirable to develop a communication plan that articulates who will initiate communication and be responsible for it; what information will be communicated; to whom (e.g. scientific community, policy-makers, lay public...); how (i.e. using which communication tools or modality); and when (i.e. at what time points before, during and after completion of the research). At institutional level (see Chapter 1: Research Institution Management), it is desirable to develop institutional policies that facilitate researchers to integrate transparency and integrity in research communication. For instance, there should be institutional guidance on accurately and comprehensively communicating on any research findings, whether positive, negative or inconclusive; and the researchers' evaluation criteria should not only be focusing on bibliometric criteria, in order to prevent a 'publish or perish' institutional culture (see Chapter 2: Ethics, Law and Scientific Integrity).



## 1707 **Points to consider and how to address them**

### 1708 ***24. Internal communication***

1709 Internal communication within a research institution or consortium is important to nurturing an  
 1710 evidence-based and ethical research culture, upholding the research standard, and staff  
 1711 engagement. An institution/consortium may consider to delegate a unit or team (e.g.  
 1712 communication unit or officer, research office, or others) to coordinate internal communication  
 1713 activities – including but not limited to the dissemination of institutional research policies and  
 1714 guidelines, updating of research project status and results, receiving inquiries from research  
 1715 personnel – via suitable communication channels. Intranet pages where the staff can easily  
 1716 access research policies, procedures and regulations, reference guidelines, organigrams, etc.  
 1717 have proven to be useful for effective internal communication. Other communication  
 1718 channels/methods that may be considered include but not limited to periodical newsletters, internal  
 1719 emails that informs about new policies or procedures, internal seminars for reflection on topics of  
 1720 common interests, and different types of meetings.

1721 For specific research projects, internal communication is normally led by principal investigators,  
 1722 and may be supported by delegated team members (e.g. study coordinators). It is desirable that  
 1723 it is executed by ways of regular and ad hoc project progress meetings, seminars, update reports  
 1724 or otherwise. Communication on project progress, funding utilization, quality and compliance  
 1725 issues, and specific challenges are common focuses.

1726 In all cases, it is important that internal communication is designed and implemented in an  
 1727 interactive rather than unidirectional way, planning spaces and tools for listening to staff and  
 1728 research participants experiences and concerns, and preparing to act upon them.

### 1729 1730 ***25. External Communication Plan***

1731 The responsibility to define and periodically revise the Communication Plan generally depends on  
 1732 the size and governance of a research project or program (e.g. single-center or multi-country,  
 1733 involving a single institution or a research consortium, etc.). For instance, it can be the task of the  
 1734 principal investigator (PI), or of the study coordinator, or of the Steering Committee, or of other(s).

1735 Once the communication plan has been defined and agreed in written, it is useful that the  
 1736 execution of the different tasks is delegated to the concerned function(s) in the research group.  
 1737 For instance, the PI and/or Steering Committee will likely be leading the communication toward  
 1738 the scientific community (point 3 below) and the policy-makers (point 7), while the study  
 1739 coordinator and field researchers will be likely leading the communication toward research  
 1740 communities (point 5). When possible, it is preferable that the communication via mainstream and  
 1741 social media (point 6) is led by professionals of communication. While this will be possible for  
 1742 bigger research institutions which usually have a Communication Unit or Department, small  
 1743 research institutions may choose to seek the advice of communication experts when possible.

#### 1744 ***1. Communication toward peers within the scientific community***

1745 As reminded by the 2016 CIOMS International ethical guidelines (Guideline 24)<sup>29</sup>, “public  
 1746 accountability is necessary for realizing the social and scientific value of health-related research.  
 1747 Therefore, researchers, sponsors, [...] have an obligation to comply with recognized publication  
 1748 ethics for research and its results. Researchers should prospectively register their studies, publish  
 1749 the results and share the data on which these results are based in a timely manner. Negative and  
 1750 inconclusive as well as positive results of all studies should be published or otherwise be made  
 1751 publicly available”. Therefore, it would be important that a Communication Plan includes:

---

<sup>29</sup> Council for International Organizations of Medical Sciences (CIOMS) *International ethical guidelines for health-related research involving humans*. 2016

1752 • The registration of the protocol in a registry recognized by the World Health Organization  
 1753 ([International Clinical Trials Registry Platform \(ICTRP\) \(who.int\)](https://www.who.int/clinical-trials-registry-platform)) - only for clinical trials and  
 1754 other prospective research in humans that fall under the policy of the International Committee  
 1755 of Medical Journal Editors (ICMJE);

1756 • Clear criteria and modalities for sharing deidentified research data (and samples) from the  
 1757 research. It is generally preferable to frame them in a general institutional policy for data (and  
 1758 samples) sharing (see Chapter 3: Scientific standards);

1759 • Plans for the dissemination of research findings (including interim results when applicable)  
 1760 through presentations at scientific conferences, (possibly) pre-prints<sup>30</sup>, and publications in  
 1761 peer-reviewed journals. It is recommended that communications at conferences and pre-prints  
 1762 are rapidly followed by submission to a peer-reviewed journal; and that for peer-reviewed  
 1763 publications, preference is given to open-access journals, and care is taken to avoid “predatory  
 1764 journals” with poor marketing and peer-review practices.

## 1765 **2. Communication toward institutions that oversee research**

1766 Any health-related research projects are overseen by at least one Research Ethics Committee or  
 1767 Institutional Review Board. Furthermore, different kind of research can be subject to the oversight  
 1768 of other bodies and institutions, such as the Regulatory Authority, the National Public Health  
 1769 Institute or others (see Chapter 2: Ethics, Law and Scientific Integrity).

1770 While it is generally the responsibility of the PI or appointed study coordinator to proactively and  
 1771 reactively communicate with such bodies, it is an organizational responsibility to create an  
 1772 institutional culture where individual researchers and staff are aware of the relevance of timely  
 1773 and transparently communication to these bodies, either for planned tasks (such as submitting  
 1774 initial protocols and amendments, sending yearly reports, etc.) or unplanned tasks (such as  
 1775 promptly communicating any events or occurrence that can impact on the feasibility, acceptability  
 1776 or findings of the research project).

## 1777 **3. Communication toward the research community**

1778 The 2021 CIOMS Consensus on Clinical Research in Resource-limited Settings indicates the  
 1779 need of formal plans on how to communicate with participants and their community in continuum  
 1780 and in a meaningful way; and the 2016 CIOMS International ethical guidelines (commentaries on  
 1781 Guideline 24)<sup>31</sup> state that “Researchers must also communicate the results of their work to the lay  
 1782 public. Ideally, researchers should take steps to promote and enhance public discussion.  
 1783 Knowledge resulting from the research should be made accessible to the communities in which  
 1784 the research was conducted, either through publication in scientific journals or through other  
 1785 channels”. Therefore, it is recommended that the Communication Plan describes how the research  
 1786 plans, tools, conduct and findings will be practically communicated and discussed with the  
 1787 research communities, on an ongoing basis.

1788 This will ideally include details on who will be responsible for this task; which relevant stakeholders  
 1789 (such as patients’ associations, local associations, community opinion leaders, community  
 1790 advisory boards, etc.) would be engaged locally; by which means the communication will be  
 1791 channelled and discussions will be organised (such as through structured meetings, mailings,  
 1792 local media, etc.); how scientific contents will be translated into lay language; and – importantly –  
 1793 a budget line specifically dedicated to activities needed for engaging the research community(ies).  
 1794

---

<sup>30</sup> Pre-prints are preliminary reports of work not yet peer-reviewed. They are uploaded in dedicated free-access servers, such as <https://www.medrxiv.org/>

<sup>31</sup> Council for International Organizations of Medical Sciences (CIOMS) *International ethical guidelines for health-related research involving humans*. 2016

#### 4. *Communication toward mainstream and social media*

Research institutions or consortia can decide to use a general or study-specific website, to inform the public on an ongoing basis about a given research program. They can also use press releases for rapidly communicating to the general public about the start of a given research program, or the achievement of a milestone during the research, or the key-facts of the research findings. Depending on the nature and mandate of the institution, the press-releases are often drafted by communication or public relation experts; however, to keep up with the principles of transparency, accountability and honesty, it is highly recommended that scientists (PI and other key-researchers) review the contents for accuracy, and that other key-information including the full protocol, analysis plan and detailed results, are rapidly made publicly available.

Any information about a research undertaking or findings which is publicly available, can be retrieved by mainstream and social media. These will further spread knowledge, but there are risks that the nature or significance of findings is misunderstood or overemphasized. Therefore, at least for those research projects that are likely to get media attention, it is highly recommended that the Communication Plan includes details on how the research plans, conduct and findings will be communicated through the media, i.e. who will be *responsible* for this task (for instance the PI, assisted by the Communication Unit or officer if any); which mainstream and/or social *media* would be preferentially targeted; by which means the contents would be channelled, e.g. a dedicated website, press-releases, messages on social media etc.; and a dedicated *budget line*. As scientists are often not trained in communication, it is also advisable to identify in the research team one or more trained spokesperson(s) responsible for communicating with the media.

#### 5. *Communication toward policy-makers in health systems*

Policy-makers in health systems – including but not limited to Ministry of Health, National Regulatory Authorities, health insurances, reimbursement commissions, those drafting standard diagnostic and treatment guidelines etc. – significantly rely on research findings for translation into policies and practices, by making decisions that are relevant to recommendations on clinical care, health and social policies, or resource allocation, and ultimately for advancing individual and public health. Therefore, it is recommended that the Communication Plan includes details on how the research plans, challenges and findings will be practically communicated to relevant policy makers. This will include details on who will be responsible for this task; which relevant stakeholders would be engaged locally, nationally or internationally; by which means the communication will be channelled and discussions will be organised (such as through policy briefs, structured meetings, sharing of de-identified key information etc.); and a dedicated budget line.

## 26. Institutional policies

All the above tasks will be easier to plan and implemented at project level, if framed into clearly-spelled out institutional policies and practices for communication. These policies would ideally include (but not be limited to):

- Institutional endorsement of relevant methodological, ethics and integrity guidelines;
- Standard operating procedures or equivalent guidance for communication with research communities and with policy-makers in health systems;
- Training for junior staff, junior researchers, master and PhD students and others, on research integrity (see Chapter 8: Education and Learning);
- Researchers' evaluation criteria that do not foster an ethos of 'publish or perish';
- The establishment of a Communication Unit or Focal Person to advise and support individual research projects.

Such an institutional framework will be useful to support researchers and research institutions when reactive communication is needed in case of crisis, e.g. in case of a safety incident during a clinical trial or in case of unproven allegations of misconduct.

## References

- Council for International Organizations of Medical Sciences (CIOMS) *International ethical guidelines for health-related research involving humans*. 2016
- Council for International Organizations of Medical Sciences (CIOMS) Working Group report: *Clinical research in resource-limited settings*. 2021
- World Medical Association (WMA) *Declaration of Helsinki – ethical principles for medical research involving human subjects*. 2013
- World Medical Association (WMA) *Declaration of Taipei – ethical considerations regarding health databases and biobanks*. 2016
- European Federation of Academies of Sciences and Humanities (ALLEA). *The European Code of Conduct for Research Integrity*. 2017
- International Committee of Medical Journal Editors (ICMJE) Recommendations on clinical trials registries and on data sharing. Available at: <https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html>
- Committee on Publication Ethics (COPE). *Principles of Transparency and Best Practice in Scholarly Publishing*. 2022. Available at: <https://publicationethics.org/sites/default/files/principles-transparency-best-practice-scholarly-publishing.pdf>
- Committee on Publication Ethics (COPE). Core practices. 2017. Available at: <https://publicationethics.org/core-practices>



## Chapter 8: Education and Learning

### Key words

*Capacity Building – Continuing Education – Education – Learning – Planning – Qualification – Training – Responsible employer – Responsibilities – Skills and expertise – Training records*

### Background and Principles

With the rapid advancement in health sciences, increasing complexity of research methods, elevating need of multidisciplinary research, and more and more stringent ethical, regulatory, administrative and quality requirements worldwide, health-related research is becoming more demanding. To fulfill their scientific and social purpose, research institutions increasingly need to ensure that their staff, as well as the staff of their collaborating partners, possess the qualifications, skills, experience and expertise needed to adequately and properly carry out their respective tasks in each research project. Effective governance of qualifications and learning of research personnel could help research institutions to uphold their research standards, in terms of scientific/methodological soundness and ethical, regulatory and quality compliance, at all stages of health-related research– from protocol development to project execution, until dissemination of findings and translation into policies and practices. In addition, it may also bring extended long-term benefits for the institutions and their research personnel, including but not limited to strengthening their reputation and facilitating future funding and research opportunities.

Therefore, it is recommended that the following activities are carefully planned, executed and monitored by the research institution, in line with its institutional mandate and goals:

- **Learning Opportunities:** Give all research staff access to adequate learning opportunities, based on their background and tasks, and on a continuous basis;
- **Expertise and Skills:** Put in place mechanisms to ensure that research staff have acquired the necessary expertise and skills to carry out their respective tasks in research projects, whether in research methods (e.g. clinical, epidemiological, qualitative or mixed-methods; good clinical/laboratory practices, etc.) or in research-related disciplines or activities (e.g. research ethics, research integrity, data management, scientific writing, planning, research contracts, administration etc.);
- **Professional Licenses:** Put in place mechanisms to ensure that where necessary, the research staff have the appropriate professional licenses to practice in compliance with the national laws and regulations;
- **Training/Learning Records:** Put in place mechanisms to document the training/learning activities and qualifications of all staff involved in research.

Within individual research projects, the principal investigators (PIs) have a particular responsibility for the overall conduct and supervision of their research projects. Thus, it is important that they check the skills and qualifications of the members of their research teams, and arrange any required training/re-training, prior to the commencement of (and, if needed, during the period of) the research project; and that they ensure proper documentation of all qualifications and learning activities.

Appropriate qualifications and learning are important pre-conditions to the achievement of the purposes of research. It is important to underline that the responsibility of research institutions to ensure that all research staff are competent and skilled in conducting their tasks, is mirrored by research staff's responsibility to acquire and maintain such knowledge and skills. Therefore, anybody involved in performing, coordinating, managing or overseeing any research-related activities under a research institution– whether clinical researchers, epidemiologists, qualitative researchers, health economists, research coordinators, quality assurance officers, lab



1912 technicians, data managers, research administrators, legal experts, field data collectors,  
 1913 community health workers, translators or otherwise – need to acquire and maintain the relevant  
 1914 qualifications and knowledge in three core domains including:

- 1915 • basic professional qualifications;
- 1916 • research concepts and standards;
- 1917 • project-specific requirements.

1918 The above recommendations are obvious to institutions that carry out interventional clinical trials,  
 1919 because clinical trials are highly regulated and there are clear qualification and training  
 1920 requirements defined in the ICH-GCP and other applicable guidelines and regulations.  
 1921 Nonetheless, a well-thought and structured approach to qualifications and training is also highly  
 1922 beneficial to institutions carrying out other health-related research, e.g. in the field of  
 1923 epidemiological, behavioural and health economic research. Irrespectively of the research  
 1924 disciplines, a proper governance of qualifications and training creates good value to research  
 1925 institutions, research personnel, research participants and the public, in the perspectives of human  
 1926 participants' protection and ethical compliance; legal, regulatory and quality compliance; research  
 1927 quality and integrity; risk management; capacity building and research talents development; and  
 1928 advancement of research methods.

## 1929 **Points to consider and how to address them**

### 1930 ***27. Basic Professional Qualifications***

1931 This refers to the fundamental professional qualifications that are required for an individual to carry  
 1932 out tasks in health-related research, e.g. medical doctors, nurses, pharmacists, dentists,  
 1933 dieticians, epidemiologists, psychologists, public health specialists, qualitative researchers, health  
 1934 economists, legal experts etc. Research institutions need to ensure that all research staff,  
 1935 including but not limited to the PI, possess the necessary qualifications and continuous education  
 1936 to adequately and properly perform their research duties. In many instances, this will also be  
 1937 checked by the Research Ethics Committee – when reviewing specific research projects – to  
 1938 ensure that the research team as a whole possesses a suitable mix of expertise for the purpose  
 1939 of the project.

1940 It is generally recommended that the responsibility to verify that adequate basic qualifications are  
 1941 attributed to the institution management, for instance to the head of a concerned department or  
 1942 unit, preferably with support of the human resources department or unit.

### 1943 ***28. Research Concepts, Standards and Skills***

1944 This refers to the core concepts, standards and skills on health-related research, and may be  
 1945 classified into six areas:

- 1946 • Research ethics and integrity (see Chapter 2: Ethics, Law and Scientific Integrity);
- 1947 • Legal, regulatory and quality requirements (see Chapter 2: Ethics, Law and Scientific Integrity);
- 1948 • Good research practice (see Chapter 3: Scientific standards);
- 1949 • Public perspectives on health-related research (see Chapter 7: Communication);
- 1950 • Research designs and methodologies (see Chapter 3: Scientific standards and Chapter 4:
- 1951 Collection, storage, and use of data and/or biological materials in health-related research);
- 1952 • Research management and operations (see Chapter 1: Research Institution Management,
- 1953 Chapter 4: Collection, storage, and use of data and/or biological materials in health-related
- 1954 research, Chapter 5: Financial Management and Budgeting and Chapter 6: Collaboration).

1955 Each of the above has different relevance, depending on the categories of staff and their  
 1956 involvement in research.

It is recommended that research institutions cultivate a learning culture, by encouraging and supporting research personnel to learn and keep themselves updated on the above concepts and standards. This can be practically achieved by disseminating the latest regulations, guidelines and standards internally (e.g. via a website, Intranet or mailing lists) and/or by organizing in-house symposia, workshops, discussion groups, public engagement events, etc. (see Chapter 7: Communication). Furthermore, the institution can encourage and support research personnel to participate in relevant external conferences, forums, symposia, training courses, etc.

### 29. Project-specific Requirements

This refers to the skills, expertise and qualifications needed to carry out specific tasks in a particular research project, as set out in research protocols and related manuals or documents.

Ideally, a qualification and learning plan covering the required competencies for each role would be in place before the start of a research project, and no activity should start if the needed skills and expertise are not available, as checked by the PI or research coordinator. Research institutions are also recommended to oversee research duty delegation and training of research teams via their institutional research oversight mechanism (see Chapter 9: Institutional Research Oversight).

### 30. Institutional Governance of Qualifications and Learning

All the above domains of qualifications and learning will be easier to plan and implement at project level, if framed into clearly-spelled out institutional policies for qualification and learning. Such institutional policies will also be helpful to cultivate a learning culture in a sustainable way over time, not depending on the inclination and motivation of a few individuals.

These policies would ideally be produced and managed in collaboration with the Human Research department or unit, because providing ongoing professional update (whether related or unrelated to research) is part of the tasks of the institution as responsible employer. Furthermore, it is recommended that the central or departmental administration is involved in these processes, given that ensuring adequate qualification and learning comes with costs, which need to be covered either at central or project level. Table 9: Core domains of qualifications and learning for research personnel below summarizes the aforesaid domains, with some examples.

**Table 9: Core domains of qualifications and learning for research personnel**

Domain	Scope	Research Personnel Responsibilities	Research Institution Responsibilities	Examples
Basic Professional Qualifications	<ul style="list-style-type: none"> <li>Professional qualifications</li> <li>Continuous education</li> </ul>	<ul style="list-style-type: none"> <li>[Upfront] acquiring the necessary professional qualifications</li> <li>[Ongoing] continuous education</li> </ul>	<ul style="list-style-type: none"> <li>Ensuring research personnel possess the necessary qualifications</li> <li>Support continuous education</li> <li>Document the qualifications</li> </ul>	<ul style="list-style-type: none"> <li>Diploma/master in epidemiology</li> <li>Diploma/master in anthropology</li> <li>Licence to exert the medical, nursing or allied health profession</li> <li>Diploma/master in administration</li> <li>Diploma/master in health economy</li> </ul>
Research Concepts, Standards & Skills	<ul style="list-style-type: none"> <li>Research ethics</li> <li>Legal, regulatory and quality requirements</li> <li>Good research practice</li> </ul>	<ul style="list-style-type: none"> <li>Learning relevant research concepts and standards via self-learning and/or participating in learning events</li> </ul>	<ul style="list-style-type: none"> <li>Ensuring research personnel possess the necessary skills</li> <li>Support training</li> <li>Document training</li> <li>Cultivating a learning culture</li> </ul>	<ul style="list-style-type: none"> <li>Master/certificate in research ethics</li> <li>Certificate in GCP</li> <li>Certificate in data management</li> <li>Master/certificate in qualitative or mixed methods</li> </ul>

Domain	Scope	Research Personnel Responsibilities	Research Institution Responsibilities	Examples
	<ul style="list-style-type: none"> <li>Public perspectives on health-related research</li> <li>Research designs and methodologies</li> <li>Research management and operations.</li> </ul>		<ul style="list-style-type: none"> <li>Disseminating latest regulations/guidelines/standards</li> <li>Supporting participation in learning events</li> </ul>	<ul style="list-style-type: none"> <li>Master/certificate in pharmacoepidemiology and pharmacovigilance</li> <li>Training in research integrity</li> <li>Training in data protection</li> <li>Training in research designs and methodologies</li> <li>Training in CONSORT, STROBE, or other methodological guidelines</li> <li>Training on SAGER guidelines</li> <li>Training in research project management</li> </ul>
Project-specific Requirements	<ul style="list-style-type: none"> <li>Project objectives, practices, procedures and requirements</li> </ul>	<ul style="list-style-type: none"> <li>PI: ensuring team members are adequately (re)trained, and document training</li> <li>Research team members: learning research protocol and related requirements</li> </ul>	<ul style="list-style-type: none"> <li>Ensuring research personnel have been adequately (re)trained</li> <li>Document training</li> </ul>	<ul style="list-style-type: none"> <li>Training in specific data management tools (e.g. REDCap for quantitative research, NVivo for qualitative research)</li> <li>Training in the study Standard Operating Procedures</li> <li>Training in national research guidelines (research host country)</li> <li>(Re)training in research ethics</li> <li>(Re)training in GCP</li> <li>Training in external or internal quality control</li> </ul>

## References

- 1986  
1987 World Medical Association (WMA) *Declaration of Helsinki – ethical principles for medical research involving human subjects*. 2013  
1988
- 1989 World Medical Association (WMA) *Declaration of Taipei – ethical considerations regarding health databases and biobanks*. 2016  
1990
- 1991 Council for International Organizations of Medical Sciences (CIOMS) *International ethical guidelines for health-related research involving humans*. 2016  
1992
- 1993 Council for International Organizations of Medical Sciences (CIOMS) Working Group report: *Clinical research in resource-limited settings*. 2021  
1994
- 1995 Council for International Organizations of Medical Sciences (CIOMS) Working Group report: *Recommended Standards of Education and Training for Health Professionals Participating in Medicines Development*. 2023 (soon to be released)  
1996  
1997
- 1998 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) *Guideline for Good Clinical Practice E6(R2) (ICH GCP)*. 2016  
1999
- 2000 Committee on Publication Ethics (COPE). Core practices. 2017. Available at:  
2001 <https://publicationethics.org/core-practices>
- 2002 European Federation of Academies of Sciences and Humanities (ALLEA). *The European Code of Conduct for Research Integrity*. 2017  
2003

## 2004 Chapter 9: Institutional Research Oversight

### 2005 Key words

2006 *Accreditation body – Auditing – External research oversight – Inspection – Institutional review*  
 2007 *board – Internal research oversight – Monitoring – Project oversight – Regulatory agency –*  
 2008 *Research Ethics Committee – Research waste – System oversight – Targeted checking*

### 2009 Background and Principles

2010 Research institutions are accountable to the public and therefore have the responsibility to  
 2011 oversee their research practices and activities to ensure that good value is generated to the  
 2012 society whilst risks are justified. Institutional research oversight refers to the system, methods and  
 2013 processes of overseeing a research institution's research infrastructure, personnel, mechanisms  
 2014 and projects in a proactive manner. Research oversight is an integral part of good research  
 2015 practice and helps:

- 2016 • secure ethical research conduct and participants' protection;
- 2017 • uphold research data quality and integrity;
- 2018 • compliance with applicable national/international guidelines, standards and regulations;
- 2019 • effective utilization of limited research resources and limit research waste; and
- 2020 • smooth project execution in accordance with project time plans and budgets.

2021 The term “oversight” is used here on purpose to avoid confusion with the sponsors' monitoring  
 2022 obligation for drug trials according to the ICH-GCP and the national laws and regulation. The  
 2023 nature and level of scrutiny of the institutional research oversight depend on the nature and level  
 2024 of research activities carried on within – or in collaboration with – the concerned institutions. Even  
 2025 when institutions act as sponsors of research projects, it may be neither necessary, nor desirable  
 2026 that they follow the ICH-GCP model for their oversight activities outside the field of drug trials.

2027 Research oversight could be organized and executed in two dimensions including:

- 2028 • **system oversight:** overseeing the research capabilities and capacity of the research  
 2029 institution to make sure that researchers and research personnel are qualified and  
 2030 competent, come from diverse backgrounds representative of local communities, and are  
 2031 gender balanced, that required facilities, equipment and tools are in place and maintained  
 2032 in good order, and that appropriate policies and procedures are established and executed  
 2033 to guide the proper conduct of research activities in compliance with the applicable ethical,  
 2034 regulatory and quality requirements;
- 2035 • **project oversight:** overseeing the setup and operation of a research project to ensure that  
 2036 the rights, safety and well-being of participants are protected, the project is progressing  
 2037 according to the time plan, funding is spent within the budget, and data is collected,  
 2038 documented, analyzed, reported and publicly disclosed/published properly.

2039 Institutional research oversight upholds scientific robustness of methods employed in study  
 2040 conduct, protection of rights, safety and well-being of human participants, research integrity, and  
 2041 quality of research outcomes. Ongoing research oversight plays an important role in preventing  
 2042 unethical practices, research waste, fraud or falsification in the conduct of research, early  
 2043 detection of protocol violations, and plagiarism in reporting.

2044

2045 **Points to consider and how to address them**

2046 ***31. Methods of Research Oversight***

2047 Depending on the statutes of a research institution and the nature of its research projects, different  
 2048 methods of oversight – including “internal research oversight” and “external research oversight”  
 2049 on different levels (see **Table 1: Example of matrix management**) – may be applied. A research  
 2050 institution has the primary responsibility to:

- 2051 • establish an internal research oversight system – for the institution itself and for its  
 2052 researchers and research teams; and
- 2053 • set out practical policies and guidance to support external research oversight by relevant  
 2054 external stakeholders.

2055 For the avoidance of doubt, a research institution does not necessarily have to use all these  
 2056 methods but may just select a combination of methods that serves its own purposes – considering  
 2057 factors such as the institution’s research objectives, the risks of its research projects, its regulatory  
 2058 environment, and expectations of its communities.

2059 **Table 10: Overview of research oversight**

Level of Research Oversight	Method of Research Oversight	
	Internal Research Oversight	External Research Oversight
Level 1	<u>Self-checking by research team:</u> As the first line project and quality control measure for a research project, targeting to discover, rectify and minimize deviations from the study protocol, applicable standards and project time/budget plans	<u>Monitoring by sponsor:</u> As the primary project and quality control measure for a sponsor’s project team, targeting to discover and rectify deviations from the study protocol and applicable standards and oversee project progress in alignment with project time/budget plans
Level 2	<u>Central oversight by institutional office/unit:</u> Representing institutional governance, targeting to oversee research compliance, resources utilization and project progress on system and project levels	<u>Auditing by sponsor/funding body/collaborator:</u> Representing organizational oversight by sponsor/funding body/collaborator, targeting to oversee research compliance, resources utilization and project progress
Level 3	<u>Ethical oversight by Institutional Research Board (IRB) (if applicable):</u> Representing institutional research ethics governance, targeting to oversee research ethics and regulatory compliance and participant protection	<u>Inspection by REC/accreditation body/regulatory agency:</u> Representing research ethics and regulatory oversight, targeting to oversee ethics, regulatory and quality compliance and data integrity for research institutions and/or their research projects

2060

2061



### 32. Internal Research Oversight

Whilst establishing an internal research oversight system is the responsibility of a research institution, execution of internal research oversight is the joint responsibility of all research stakeholders within the institution – including institutional management, researchers/research personnel and other delegated units/persons. Table 11 provides an outline of an internal research oversight system for reference.

**Table 11: Outline of an internal research oversight system**

Level of Oversight	Primary Responsibility	Possible Delegate	Methodology & Scope	Institution's Role
Level 1: Self-checking by research team	Researcher	Study coordinator, research assistant	<ul style="list-style-type: none"> <li>Full checking</li> <li>Targeted checking</li> </ul>	<ul style="list-style-type: none"> <li>Developing guidance documents and forms for use by researchers and research teams</li> <li>Establishing and operating a mechanism for advising and receiving reports from researchers</li> </ul>
Level 2: Central oversight by institutional office/unit	Research oversight committee, central research office, quality management department, or equivalent	Internal quality specialist, contracted auditor	<ul style="list-style-type: none"> <li>System oversight: Routine or for-cause review</li> <li>Project oversight: All projects or selected projects</li> </ul>	<ul style="list-style-type: none"> <li>Delegating an institutional office/unit to perform central oversight</li> <li>Establishing a mechanism to select units/teams/projects for checking</li> <li>Developing guidance documents and forms for system oversight and project oversight</li> </ul>
Level 3: Ethical and regulatory oversight by IRB (if applicable)	IRB (if applicable)	IRB member, contracted auditor	<ul style="list-style-type: none"> <li>Ethical and regulatory oversight</li> </ul>	<ul style="list-style-type: none"> <li>Authorizing the IRB to perform ethical and regulatory oversight</li> <li>Receiving feedback/reports from IRB</li> <li>Procuring relevant researchers and institutional offices/units to respond to IRB's feedback</li> </ul>

2069 **Level 1 Oversight:** Researchers play an important role in conceiving, designing, conducting and  
 2070 reporting research, and also assume the primary responsibility for ensuring compliance and quality  
 2071 of their research projects. They should therefore maintain adequate and verifiable research  
 2072 records and delegate team member(s) to perform first-line checking of their research works.  
 2073 Depending on a project's nature, risks and applicable ethical, regulatory and quality requirements,  
 2074 self-checking could be performed by way of:

- 2075 • **full checking:** reconstructing and verifying the entire research process against the  
 2076 research protocol and applicable standards by checking all research-related records and  
 2077 data, including but not limited to source documents, clinical notes, case report forms,  
 2078 participant-administered questionnaires, researcher training records and equipment  
 2079 maintenance records; or
- 2080 • **targeted checking:** checking of only pre-defined important records and process (e.g.  
 2081 informed consent documents, data supporting the primary objective of the project) –  
 2082 usually by applying a risk-based approach – to ensure that the key research data are  
 2083 reliable and the most important requirements and conditions are fulfilled.

2084 Research institutions should provide guidance and support to researchers and their research  
 2085 teams on performing self-checking of their projects. Issuance of guidelines and checking tools  
 2086 (e.g. checklists, reporting forms) and organization of training are valuable options.

2087 **Level 2 Oversight:** Research institutions are responsible for maintaining a research-friendly  
 2088 environment that helps researchers and research personnel to adopt good research practice and  
 2089 undertake research with good compliance and integrity. The higher the research activities are, the  
 2090 higher is the need to set up a central oversight system, operated by a delegated research oversight  
 2091 committee, central research office, quality management department, or equivalent unit. Central  
 2092 research oversight could be performed from the dimension of system oversight or project  
 2093 oversight, as introduced in the background and principles section above.

2094 For sizeable research institutions with multiple layers/units, system review could be performed  
 2095 regularly as a routine exercise for individual departments/units/specialties rather than for the entire  
 2096 institution in one go. Extra reviews could be organized as needed, for instance, in case of any  
 2097 concern or complaint.

2098 For smooth execution of project review, institutions may establish a review plan with pre-defined  
 2099 check-points for each research project. In case an institution is running a large number of ongoing  
 2100 projects, it may not be practically feasible to review every single project. In this regard, the  
 2101 institution may establish a mechanism for selecting a manageable number of projects for review  
 2102 within each defined period (e.g. annually). Again, a risk-based approach taking into consideration  
 2103 certain core risk factors (e.g. involvement of vulnerable participants, enrolment of a large number  
 2104 of participants, and application of investigational interventions) is recommended.

2105 **Level 3 Oversight:** Some research institutions may establish and operate their own institutional  
 2106 review boards (IRBs) to oversee research ethics and regulatory matters, and in this case such  
 2107 IRBs may undertake a more independent role in performing another level of research oversight –  
 2108 in particular with focus on protecting the rights, safety and well-being of research participants and  
 2109 their affiliated communities. Like central research oversight as described in the previous  
 2110 paragraph, ethical and regulatory oversight could be performed from the dimension of systems or  
 2111 projects. To facilitate this, research institutions should give their IRBs due authority and establish  
 2112 a mechanism to require relevant researchers and institutional offices/units to cooperate with the  
 2113 IRBs and respond to their feedback.

2114

### 33. External Research Oversight

Health-related research is more and more organized in a collaborative manner, in anticipation to generate better value for benefiting a wider population. Research projects are therefore more often subject to external oversight by collaborating parties, whether commercial sponsors, other collaborating institutions, funding bodies, accreditation bodies or regulatory agencies.

Different external bodies may have different oversight requirements, depending on their roles and involvement in the corresponding research projects or activities. For instance, commercial sponsors may have their focus on protocol compliance, whilst funding bodies may pay more attention to resource utilization and budget control.

Although research institutions are on a relatively passive role in terms of external research oversight, they should establish appropriate institutional policies and guidance for researchers and relevant institutional offices/units in facilitating such oversight activities, in particular on:

- personnel records maintenance: maintaining and retaining updated CVs, qualification certificates and training records for researchers and research personnel;
- facility and equipment maintenance: maintaining and retaining corrective/preventive maintenance and calibration records for relevant research facilities and equipment;
- research documents and records maintenance: generating and retaining all essential research records such as informed consent documents, source records, case report forms and survey forms – whether in paper, electronic or other formats – during the period of each project and the required duration after project closure.

Proper document retention is a key prerequisite for supporting external oversight. However, long-term document retention is a common challenge for researchers. Research institutions are advised to allocate/identify sufficient document storage space (within or outside the institution) and establish a research document management mechanism to facilitate long-term document archiving and document retrieval as needed.

### 34. Continuous Improvement

Institutional research oversight is not a one-time exercise. In addition to the subject matter of each review, it is more important for encouraging the institution's continuous improvement. It is therefore necessary to incorporate a positive feedback loop in the research oversight systems to allow:

- documentation of identified observations/findings;
- submitting amendments to relevant REC and NRA prior to implementing them;
- reporting of identified observations/findings to researchers and institutional offices/units;
- escalation of identified observations/findings to institutional management;
- evaluation of the root causes of identified observations/findings;
- implementation of corrective and/or improvement actions to attain institutional improvement in terms of research capabilities, quality and compliance.

2153 **References**

- 2154 Council for International Organizations of Medical Sciences (CIOMS) *International ethical*  
2155 *guidelines for health-related research involving humans*. 2016
- 2156 Council for International Organizations of Medical Sciences (CIOMS) Working Group report:  
2157 *Clinical research in resource-limited settings*. 2021
- 2158 World Medical Association (WMA) *Declaration of Helsinki – ethical principles for medical*  
2159 *research involving human subjects*. 2013
- 2160 World Medical Association (WMA) *Declaration of Taipei – ethical considerations regarding*  
2161 *health databases and biobanks*. 2016
- 2162 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for  
2163 Human Use (ICH) *Guideline for Good Clinical Practice E6(R2) (ICH GCP)*. 2016
- 2164 World Health Organization (WHO) *Standards and Operational Guidance for Ethics Review of*  
2165 *Health-Related Research with Human*. 2011
- 2166 United Nations Educational, Scientific and Cultural Organization (UNESCO) *Recommendation*  
2167 *on Science and Scientific Researchers*. 2017
- 2168 AAMC Task Force on Financial Conflicts of Interest in Clinical Research. Protecting subjects,  
2169 preserving trust, promoting progress I: policy and guidelines for the oversight of individual financial  
2170 interests in human subjects research. *Acad Med*. 2003 Feb;78(2):225-36. PMID: 12584106.
- 2171 Teaching the responsible conduct of research in humans. Chapter 5 Monitor Research by The  
2172 Office of Research Integrity. US Department of Health and Human Services.  
2173 <https://ori.hhs.gov/education/products/ucla/chapter5/default.htm>.
- 2174 National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's  
2175 Investment in Academic Research: A New Regulatory Framework for the 21st Century.  
2176 Washington, DC: The National Academies Press. doi: 10.17226/21824.
- 2177 Indian Council on Medical Research (ICMR) National Ethical Guidelines for Biomedical and health  
2178 Research involving Human participants, 2016.
- 2179

2180

## 2181 **Annex: Points to Consider in Establishing Good Governance**

## 2182 **Practice for Research Institutions**

### 2183 **Chapter 8: Research Institution Management**

- 2184 1. Research Scope, Mission, Vision and Values
- 2185 2. Organizational Structure, Leadership and Culture
- 2186 3. Knowledge Management, Quality Management and Risk Management
- 2187 4. Corporate Communications

### 2188 **Chapter 2: Ethics, Law and Scientific Integrity**

- 2189 5. Responsibilities towards research participants
- 2190 6. Responsibilities towards researchers and research team members
- 2191 7. Institutional culture to enhance working with scientific integrity
- 2192 8. Accountability, transparency and participation

### 2193 **Chapter 3: Scientific standards**

- 2194 9. Awareness and coordination of proposed and ongoing research
- 2195 10. Scientific value and appropriate research plan
- 2196 11. Scientific rigor—review and training

### 2197 **Chapter 4: Collection, storage, and use of data and/or biological**

### 2198 **materials in health-related research**

- 2199 12. Responsibilities towards the participants
- 2200 13. Access and transfer of data and biological materials
- 2201 14. Biobank & Databank
- 2202 15. Operational requirements for the collection, storage and use of data and biological
- 2203 materials
- 2204 16. Data lifecycle

### 2205 **Chapter 5: Financial Management and Budgeting**

- 2206 17. Institutional Resources Planning
- 2207 18. Project Budgeting
- 2208 19. Financial Administration
- 2209 20. Financial Compliance

### 2210 **Chapter 6: Collaboration**

- 2211 21. Identification of Suitable Collaborators
- 2212 22. Collaboration Plan and Concerted Execution
- 2213 23. Collaboration Agreements

### 2214 **Chapter 7: Communication**

- 2215 24. Internal communication
- 2216 25. External communication plan
- 2217 26. Institutional policies

2218



**2219 Chapter 8: Education and learning**

- 2220 27. Basic Professional Qualifications
- 2221 28. Research Concepts, Standards and Skills
- 2222 29. Project-specific Requirements
- 2223 30. Institutional Governance of Qualifications and Learning

**2224 Chapter 9: Institutional Research Oversight**

- 2225 31. Methods of Research Oversight
- 2226 32. Internal Research Oversight
- 2227 33. External Research Oversight
- 2228 34. Continuous Improvement

2229

## 2230 Participants in the working group

Name	Affiliation	Country
Dominique Sprumont (chair)	Comité d'éthique de la recherche du canton de Vaud (CER-VD) Institute of Health Law, University of Neuchâtel, WMA academic partner	Switzerland
Aline Sigrist (secretary 2022-2023)	Institute of Health Law, University of Neuchâtel, WMA academic partner	Switzerland
Annie Volet (secretary 2021)	Institute of Health Law, University of Neuchâtel, WMA academic partner	Switzerland
Anant Bhan	Department of Community Medicine, Yenepoya Medical College The Centre for Ethics, Yenepoya University, Mangaluru	India
Johannes van Delden	Johannes JM van Delden (MD, PhD), Department Bioethics and Health Humanities, University Medical Center Utrecht, Utrecht University, the Netherlands.	The Netherlands
Ames Dhai	School of Clinical Medicine, University of the Witwatersrand, South Africa	South Africa
Kim Ellefsen	Director of the Sponsor research Office, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne.	Switzerland
Morenike Folayan	New HIV Vaccine and Microbicide Advocacy Society (NHVMAS)	Nigeria
Christine Grady	Department of Bioethics NIH Clinical Center	USA
Marie Hirtle	Centre for Applied Ethics, REB - McGill University Health Centre (MUHC)	Canada
Rosanna Lagos	Centro para Vacunas en Desarrollo, Santiago Hospital de Niños de Santiago	Chile
Dirk Lanzerath	European Network of Research Ethics Associations (EUREC)	Germany
Roli Mathur	Dr Roli Matur ICMR Bioethics Unit, Indian Council of Medical Research WHO Collaborating Centre for Strengthening Ethics in Biomedical & Health Research	India
Kotone Matsuyama	Department of Health Policy and Management, Nippon Medical School	Japan
Winfred Nazziwa	Uganda National Council for Science and Technology (UNCST) African Vaccine Regulatory Forum (AVAREF)	Uganda
Francine Ntoumi	Fondation Congolaise pour la Recherche Médicale	Congo Brazzaville
Lembit Rago	Council of International Organizations of Medical Sciences (CIOMS)	Switzerland
Raffaella Ravinetto	Institutional Review Board, Institute of Tropical Medicine, Antwerp	Belgium
Andreas Reis	Global Health Ethics, Health Systems and Innovation Cluster World Health Organization (WHO)	Switzerland
Vladislava Talanova	Institute of Health Law, University of Neuchâtel, WMA academic partner	Switzerland
Creany Wong	The University of Hong Kong Clinical Trials Centre (HKU-CTC)	Hong Kong/China
Henry Yau	International Clinical Trial Center Network (ICN)	Hong Kong/China
Zhu Wei	Shanghai Ethics Committee for Clinical Research (SECCR)	China

2231